var title_f2_39_2672="Aryepiglottic fold cyst";
var content_f2_39_2672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cyst of aryepiglottic fold",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note obstruction of the glottic opening.",
"    <div class=\"footnotes\">",
"     C: cyst.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ellen S Deutsch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_39_2672=[""].join("\n");
var outline_f2_39_2672=null;
var title_f2_39_2673="Basic case 11 with answer";
var content_f2_39_2673=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Ectopic atrial rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 95px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rhythm strip in lead II showing ectopic atrial rhythm with inverted P waves which represent a low atrial focus with retrograde activation of the atrium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary L Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_39_2673=[""].join("\n");
var outline_f2_39_2673=null;
var title_f2_39_2674="Scabies infant foot 2";
var content_f2_39_2674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous and hyperpigmented papules and crusts are present on the foot of this child with scabies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_39_2674=[""].join("\n");
var outline_f2_39_2674=null;
var title_f2_39_2675="Leukoplakia - tongue";
var content_f2_39_2675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leukoplakia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A white plaque is present on the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_39_2675=[""].join("\n");
var outline_f2_39_2675=null;
var title_f2_39_2676="Barrett's esophagus";
var content_f2_39_2676=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Barrett's esophagus (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/39/2676/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/39/2676/contributors\" id=\"au6628\">",
"       Stuart J Spechler, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/39/2676/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/39/2676/contributors\" id=\"se5165\">",
"       Nicholas J Talley, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/39/2676/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/39/2676/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?2/39/2676?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BARRETT'S ESOPHAGUS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The esophagus is the tube that connects the mouth with the stomach (",
"     <a class=\"graphic graphic_figure graphicRef79301 \" href=\"UTD.htm?8/28/8642\">",
"      figure 1",
"     </a>",
"     ). Barrett's esophagus occurs when the normal cells that line the lower part of the esophagus (called squamous cells) are replaced by a different cell type (called intestinal cells). This process usually occurs as a result of repetitive damage to the inside of the esophagus.",
"    </p>",
"    <p>",
"     The most common cause of Barrett's esophagus is longstanding acid reflux disease, called gastroesophageal reflux disease (GERD). In people with GERD, the esophagus is repeatedly exposed to excessive amounts of stomach acid. Interestingly, the intestinal cells of Barrett's esophagus are more resistant to acid than squamous cells, suggesting that these cells may develop to protect the esophagus from acid exposure. The problem is that the intestinal cells have a risk of transforming into cancer cells.",
"    </p>",
"    <p>",
"     More detailed information about Barrett's esophagus is available separately. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1161?source=see_link\">",
"      \"Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"      \"Management of Barrett's esophagus\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      BARRETT'S ESOPHAGUS RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of factors that increase the risk of developing Barrett's esophagus:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Age",
"     </span>",
"     &nbsp;&mdash;&nbsp;Barrett's esophagus is most commonly diagnosed in middle-aged and older adults; the average age at diagnosis is 55 years. Children can develop Barrett's esophagus, but rarely before the age of five years.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Gender",
"     </span>",
"     &nbsp;&mdash;&nbsp;Men are more commonly diagnosed with Barrett's esophagus than women.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Ethnic background",
"     </span>",
"     &nbsp;&mdash;&nbsp;Barrett's esophagus is equally common in white and Hispanic populations and is uncommon in black and Asian populations.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Lifestyle",
"     </span>",
"     &nbsp;&mdash;&nbsp;Smokers are more commonly diagnosed with Barrett's esophagus than nonsmokers.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      BARRETT'S ESOPHAGUS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Barrett's esophagus itself produces no symptoms. Instead, most people seek help because of symptoms of GERD, including heartburn, regurgitation of stomach contents, and, less commonly, difficulty swallowing.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      BARRETT'S ESOPHAGUS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     A healthcare provider may suspect Barrett's esophagus based upon a person's symptoms and the risk factors described above. An endoscopy is needed to confirm the abnormal esophageal lining.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Upper endoscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Upper endoscopy is a test that allows your doctor to see the inside of the esophagus and stomach. Before the test, you are sedated to prevent discomfort. The doctor will insert a thin lighted tube into the esophagus. The tube has a camera, which allows the doctor to see the lining of the esophagus.",
"    </p>",
"    <p>",
"     Normally, the lining should appear pale and glossy; in a person with Barrett's esophagus, the lining appears pink or red and velvety. The doctor will remove a small sample of the lining during the endoscopy so that it can be examined with a microscope for signs of Barrett's. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"      \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Endoscopy detects most (80 percent) but not all cases of Barrett's esophagus. Individual variations in the anatomy of the esophagus and the area where it meets the stomach can make the diagnosis of Barrett's esophagus difficult in some people.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      BARRETT'S ESOPHAGUS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The goal of treatment in patients with Barrett's esophagus is to control reflux symptoms. Aggressive reflux treatment may be more effective in preventing cancer than treating only when there are reflux symptoms. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"      \"Management of Barrett's esophagus\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Behavior and diet changes",
"     </span>",
"     &nbsp;&mdash;&nbsp;The first priority in treating Barrett's esophagus is to stop the damage to the esophageal lining, which usually means eliminating acid reflux. Most patients are advised to avoid certain foods and behaviors that increase the risk of reflux. Foods that can worsen reflux include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Chocolate",
"      </li>",
"      <li>",
"       Coffee and tea",
"      </li>",
"      <li>",
"       Peppermint",
"      </li>",
"      <li>",
"       Alcohol",
"      </li>",
"      <li>",
"       Fatty foods",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Acidic juices such as orange or tomato juice may also worsen symptoms. Carbonated beverages can be a problem for some people. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Behaviors that can worsen reflux include eating meals just before going to bed, lying down after eating meals, and eating very large meals. Placing bricks or blocks under the head of the bed (to raise it by about six inches) help to keep acid in the stomach while sleeping. It is not helpful to use additional pillows under the head.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;A clinician may prescribe medications that reduce the amount of acid produced by the stomach. A class of medications called proton pump inhibitors is commonly recommended. Five different formulations (some of which are available as a generic) are currently available: omeprazole (Prilosec&reg;), esomeprazole (Nexium&reg;), lansoprazole (Prevacid&reg;), rabeprazole (Aciphex&reg;) and pantoprazole (Protonix&reg;); any of these is an acceptable option.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who have severe reflux may benefit from surgical procedures to reduce reflux. Surgery is not the best treatment in all situations, so you should discuss this option with your doctor. More information about surgical treatments for reflux is available in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      BARRETT'S ESOPHAGUS COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     One potential complication of Barrett's esophagus is that, over time, the abnormal esophageal lining can develop early precancerous changes. The early changes may progress to advanced precancerous changes, and finally to frank esophageal cancer. If undetected, this cancer can spread and invade surrounding tissues.",
"    </p>",
"    <p>",
"     However, progression to cancer is uncommon for any individual patient; studies that follow patients with Barrett's esophagus reveal that only 0.5 percent of patients develop esophageal cancer per year. Furthermore, patients with Barrett's esophagus appear to live approximately as long as people who are free of this condition. Patients often die of other causes before Barrett's esophagus progresses to cancer.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      BARRETT'S ESOPHAGUS MONITORING",
"     </span>",
"    </p>",
"    <p>",
"     Monitoring for precancerous changes is recommended for most patients with Barrett's esophagus. At this time, monitoring includes periodic endoscopy with tissue biopsy. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"      \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Although new technologies for monitoring are on the horizon, most are still considered to be experimental. Experts do not agree about the usefulness of monitoring. The benefits of monitoring depend upon each person's chance of developing esophageal cancer, which may be difficult to determine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Benefits",
"     </span>",
"     &nbsp;&mdash;&nbsp;Reasons to perform endoscopic monitoring include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Monitoring can detect precancerous changes (dysplasia) in the esophageal lining. These changes may indicate that the person has an increased risk of cancer. Early detection may be especially important for younger patients.",
"      </li>",
"      <li>",
"       Monitoring may detect cancer at an earlier stage, when it can be more effectively treated.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Limitations",
"     </span>",
"     &nbsp;&mdash;&nbsp;However, not all patients will benefit from endoscopic monitoring.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Progression of Barrett's esophagus to cancer is uncommon.",
"      </li>",
"      <li>",
"       Endoscopy carries certain risks and often causes anxiety.",
"      </li>",
"      <li>",
"       Endoscopy may miss areas with premalignant changes or cancer.",
"      </li>",
"      <li>",
"       Even if endoscopy detects cancer, the available treatment options may have unacceptably high risks.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      PRECANCEROUS CHANGES AND BARRETT'S ESOPHAGUS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Confirmation and staging",
"     </span>",
"     &nbsp;&mdash;&nbsp;If precancerous changes are discovered, they should be confirmed by a second pathologist, an expert in examining tissue samples. It is sometimes difficult to correctly identify precancerous changes, especially when there is inflammation (usually caused by the ongoing reflux of acid). Many clinicians increase the dose of acid-suppressing medications in this situation.",
"    </p>",
"    <p>",
"     The precancerous changes must then be graded as \"low grade dysplasia\" or \"high grade dysplasia,\" depending upon their severity.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Treatment options",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with low grade dysplasia are usually told to increase their dose of acid suppressing medication and undergo a repeat endoscopy within six months.",
"    </p>",
"    <p>",
"     A person with high grade dysplasia has more limited options. The management of this condition is controversial. The optimal treatment depends upon the person's age and health and the patient and physician's preference. The options include removal of the esophagus (esophagectomy) and removing (eg, endoscopic mucosal resection) or destroying (eg, radiofrequency ablation, photodynamic or other ablation therapies) the abnormal tissue.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Esophagectomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Esophagectomy is the only treatment for high-grade dysplasia that clearly removes all of the precancerous tissue, although this treatment also has the highest rates of procedure-related death and long-term complications. Reasons to remove the esophagus (esophagectomy) include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cancer is already present in some patients with high grade dysplasia.",
"      </li>",
"      <li>",
"       Not removing the esophagus would mean that the person would need frequent monitoring with endoscopy and numerous biopsies.",
"      </li>",
"      <li>",
"       Once Barrett's esophagus has progressed to high grade dysplasia, further progression to cancer is common and may occur rapidly.",
"      </li>",
"      <li>",
"       Esophageal cancer that begins to invade other tissue may be incurable.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     However, esophagectomy may not be necessary in all patients. In addition, the surgery has some serious risks. Anyone who chooses to have esophagectomy should have it performed by an experienced physician in a hospital where the procedure is performed frequently. In one study of 340 esophagectomies performed at 25 different hospitals, the mortality rate was 3 percent for patients who had the operation at institutions that did five or more esophagectomies per year, compared to 12 percent for patients treated at institutions where the operation was performed less frequently [",
"     <a class=\"abstract\" href=\"UTD.htm?2/39/2676/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Reasons to avoid esophagectomy include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Even advanced premalignant changes do not always progress to esophageal cancer. Studies suggest that progression to cancer occurs in 5 to 8 percent of patients with high-grade dysplasia each year.",
"      </li>",
"      <li>",
"       Advanced premalignant changes may actually regress in some patients.",
"      </li>",
"      <li>",
"       Vigilant endoscopic monitoring can be used to detect early cancer.",
"      </li>",
"      <li>",
"       Esophagectomy has approximately a 2 to 5 percent chance of leading to death.",
"      </li>",
"      <li>",
"       Esophagectomy can have other serious complications that worsen quality of life.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5528691\">",
"     <span class=\"h3\">",
"      Endoscopic treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Endoscopic treatments may be an alternative to surgical therapy in some patients with high-grade dysplasia. Some techniques have also been tried in patients with low-grade dysplasia. There is considerable controversy regarding when to use these endoscopic approaches. Furthermore, even in patients whose Barrett's tissue is destroyed with treatment, some Barrett's tissue may remain in the esophagus, which still has the potential to progress to dysplasia and cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h4\">",
"      Endoscopic mucosal resection",
"     </span>",
"    </p>",
"    <p>",
"     Endoscopic mucosal resection (EMR) involves the removal of a large but thin area of esophageal tissue through an endoscope. EMR provides large tissue specimens that can be examined by the pathologist to determine the character and extent of the lesion and determine if an adequate amount of tissue was removed. Therefore, it can help to confirm the person's diagnosis and completely treat the abnormality (if the abnormal tissue is removed completely). However, this technique is generally performed only in highly specialized centers.",
"    </p>",
"    <p>",
"     EMR is a reasonable alternative to esophagectomy in certain patients with high-grade dysplasia or early stage esophageal cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H118930433\">",
"     <span class=\"h4\">",
"      Radiofrequency ablation",
"     </span>",
"    </p>",
"    <p>",
"     Radiofrequency ablation (RFA) is an endoscopic procedure that uses radiofrequency energy (microwaves) to destroy the Barrett&rsquo;s cells. In short-term studies, RFA has been shown to prevent high-grade dysplasia from progressing to cancer and to prevent low-grade dysplasia from developing more advanced features. However, there is limited information on the long-term outcome of this approach. Furthermore, RFA is expensive and presently available primarily in academic medical centers. In up to 5 percent of patients, the procedure causes a complication, such as narrowing of the esophagus, which may require repeated treatments to open the esophagus.",
"    </p>",
"    <p>",
"     Another concern with RFA is that patients with high-grade dysplasia may have areas of invasive cancer that are not treated adequately. In all cases, the patient and family should discuss the risks and benefits of possible treatments with a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h4\">",
"      Photodynamic therapy",
"     </span>",
"    </p>",
"    <p>",
"     Photodynamic therapy is a treatment that uses chemical agents, known as photosensitizers, to kill certain types of cells (such as Barrett's cells) when the cells are exposed to a specific type of light. Patients are given the photosensitizer medication into a vein and then undergo endoscopy. During the endoscopy, a laser light is used to activate the photosensitizer and destroy the Barrett's tissue.",
"    </p>",
"    <p>",
"     However, there is limited information on the long-term outcome of this approach. Furthermore, photodynamic therapy is expensive and available in only a small number of academic medical centers. In up to 40 percent of patients, the procedure causes a complication, such as narrowing of the esophagus, which may require repeated treatments to open the esophagus.",
"    </p>",
"    <p>",
"     Another concern with photodynamic therapy is that patients with high-grade dysplasia may have areas of invasive cancer that are not treated adequately. In all cases, the patient and family should discuss the risks and benefits of possible treatments with a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h3\">",
"      Observation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some experts recommend that aggressive treatment (esophagectomy) for high-grade dysplasia be delayed until there is evidence of progression to cancer. After the person is diagnosed with high-grade dysplasia, he or she would be monitored closely with endoscopy every three to six months. The benefits and limits of monitoring are discussed above. (See",
"     <a class=\"local\" href=\"#H15\">",
"      'Barrett's esophagus monitoring'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     We generally do not recommend close monitoring for people with high-grade dysplasia because few published data directly support its safety and efficacy. The optimal treatment strategy should be discussed with a knowledgeable and experienced gastroenterologist.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     Despite the uncertainties surrounding the monitoring and treatment of Barrett's esophagus, there is consensus on one matter: The available options should be tailored to the individual patient. The following are general guidelines:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       People with Barrett's esophagus should be treated to decrease reflux symptoms. This may improve or eliminate symptoms of heartburn, reduce inflammation, help prevent complications, and improve the accuracy of endoscopy results.",
"      </li>",
"      <li>",
"       People without evidence of precancerous changes (ie, no dysplasia) or esophageal cancer should have endoscopy with biopsies. The first follow-up endoscopy should be done one year after Barrett's is diagnosed. Endoscopy may then be done every three to five years, unless there are other medical conditions that increase the small risks associated with endoscopy.",
"      </li>",
"      <li>",
"       If endoscopy reveals a precancerous change (dysplasia), this finding should be confirmed by at least one expert; if necessary, additional tissue samples should be collected to resolve any doubt.",
"      </li>",
"      <li>",
"       People with",
"       <strong>",
"        early",
"       </strong>",
"       precancerous changes (low grade dysplasia) generally are advised to have repeat endoscopy at 6 and 12 months, followed by annual endoscopy if the lesion does not appear to progress. In some cases, RFA may be considered to treat low grade dysplasia.",
"      </li>",
"      <li>",
"       People with",
"       <strong>",
"        advanced",
"       </strong>",
"       precancerous changes (high grade dysplasia) should have their diagnosis confirmed by an expert. There are several options for management. (See",
"       <a class=\"local\" href=\"#H20\">",
"        'Treatment options'",
"       </a>",
"       above.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H27\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784917961\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23444132\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/29/13778?source=see_link\">",
"      Patient information: Barrett's esophagus (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/17/9491?source=see_link\">",
"      Patient information: Esophageal cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23444149\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13750?source=see_link\">",
"      Autofluorescence endoscopy for Barrett's esophagus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10858?source=see_link\">",
"      Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1161?source=see_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=see_link\">",
"      Narrow band imaging in Barrett's esophagus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/12/8391?source=see_link\">",
"      Pathogenesis of Barrett's esophagus and its malignant transformation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=see_link\">",
"      Photodynamic therapy for ablation of Barrett's esophagus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/53/41817?source=see_link\">",
"      Radiofrequency ablation for Barrett's esophagus",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Gastroenterological Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gastro.org/\">",
"      www.gastro.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American College of Gastroenterology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.acg.gi.org/\">",
"      www.acg.gi.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society for Gastrointestinal Endoscopy",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.askasge.org/\">",
"      www.askasge.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?2/39/2676/abstract/1-7\">",
"      1-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?2/39/2676?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2676/abstract/1\">",
"      Swisher SG, Deford L, Merriman KW, et al. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg 2000; 119:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2676/abstract/2\">",
"      Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2676/abstract/3\">",
"      Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 2001; 111:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2676/abstract/4\">",
"      Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003; 98:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2676/abstract/5\">",
"      Shaheen NJ, Inadomi JM, Overholt BF, Sharma P. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut 2004; 53:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2676/abstract/6\">",
"      Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006; 63:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2676/abstract/7\">",
"      Wang KK, Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008; 103:788.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f2_39_2676=[""].join("\n");
var outline_f2_39_2676=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BARRETT'S ESOPHAGUS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           BARRETT'S ESOPHAGUS RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           BARRETT'S ESOPHAGUS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           BARRETT'S ESOPHAGUS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           BARRETT'S ESOPHAGUS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           BARRETT'S ESOPHAGUS COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           BARRETT'S ESOPHAGUS MONITORING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           PRECANCEROUS CHANGES AND BARRETT'S ESOPHAGUS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H27\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/28/8642\" title=\"figure 1\">",
"           GERD PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f2_39_2677="Acrivastine and pseudoephedrine: Patient drug information";
var content_f2_39_2677=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acrivastine and pseudoephedrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/59/31669?source=see_link\">",
"     see \"Acrivastine and pseudoephedrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Semprex&reg;-D",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701436",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acrivastine, pseudoephedrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Kidney disease, very bad heart disease, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel block, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10997 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_39_2677=[""].join("\n");
var outline_f2_39_2677=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130333\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017426\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017428\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017427\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017432\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017433\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017435\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017430\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017431\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017436\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017437\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/59/31669?source=related_link\">",
"      Acrivastine and pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_39_2678="Superior mesenteric artery syndrome";
var content_f2_39_2678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Superior mesenteric artery syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 635px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The superior mesenteric artery arises from the anterior aspect of the aorta at the level of the L1 vertebral body. It is enveloped in fatty and lymphatic tissue and extends in a caudal direction at an acute angle into the mesentery. In the majority of patients, the normal angle between the superior mesenteric artery and the aorta is between 38 and 65 degrees.&nbsp;Superior mesenteric artery syndrome is characterized by compression of the third portion of the duodenum due to narrowing of the space between the superior mesenteric artery and aorta and is primarily attributed to loss of the intervening mesenteric fat pad.&nbsp;With superior mesenteric artery syndrome, the angle between the superior mesenteric artery and the aorta can be narrowed to as little as 6 degrees.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_39_2678=[""].join("\n");
var outline_f2_39_2678=null;
var title_f2_39_2679="Evaluation of the child with back pain";
var content_f2_39_2679=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the child with back pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/39/2679/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/39/2679/contributors\">",
"     Peter A Nigrovic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/39/2679/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/39/2679/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/39/2679/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/39/2679/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/39/2679/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/39/2679/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Back pain is an uncommon presenting complaint in children. Although the etiology of back pain usually is benign, occasionally a significant congenital or acquired process is found. Of the latter, infectious, rheumatic, and neoplastic processes are most likely to cause serious problems (",
"    <a class=\"graphic graphic_table graphicRef54179 \" href=\"UTD.htm?12/40/12941\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The evaluation of the child with back pain is reviewed here. The etiology of back pain in children and adolescents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19162?source=see_link\">",
"     \"Back pain in children and adolescents: Overview of causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite presenting infrequently to the pediatric clinic, transient back pain is a relatively common occurrence in children, particularly after early adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. One large Scandinavian survey including more than 5000 children and young adults found that 7 percent of 12-year-olds had experienced at least one episode of low-back pain, the cumulative incidence increasing to 50 percent by age 18 years (girls) and 20 years (boys) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/6\">",
"     6",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef51206 \" href=\"UTD.htm?5/42/5806\">",
"     figure 1",
"    </a>",
"    ). The prevalence on any given day was noted to be approximately 1 percent for 12-year-olds and 5 percent for 15-year-olds, rising to 10 percent by the early 20s (",
"    <a class=\"graphic graphic_figure graphicRef54659 \" href=\"UTD.htm?17/44/18125\">",
"     figure 2",
"    </a>",
"    ). Most children with back pain have mild, nondisabling symptoms and do not seek medical care. Noted associations include female gender, increased time spent watching TV, negative scores on affect scales, and a family history of back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Back pain is an uncommon presenting complaint in the pediatric emergency department, accounting for fewer than 0.4 percent of all visits in one inner-city series [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/9\">",
"     9",
"    </a>",
"    ]. Almost 90 percent of the children had symptoms for less than four weeks at the time of presentation. Approximately one-half of the episodes of back pain in all age groups were caused by musculoskeletal trauma, whereas the remainder were divided among infections (eg, urinary tract infection [UTI] or viral illness) (9 percent), idiopathic pain (13 percent), sickle cell pain crisis (13 percent), and miscellaneous causes (6 percent). In the primary care setting, as well as in some specialty clinics, overloaded school backpacks are a potential cause of back pain in children, though prospective study has not invariably confirmed a correlation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Back pain that persists or worsens over the course of time deserves careful attention. In one series, 32 of 61 children presenting to an orthopedic clinic with back pain had serious underlying pathology, including nine with either infection or tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/13\">",
"     13",
"    </a>",
"    ]. A lower incidence of serious underlying pathology was documented by a musculoskeletal referral group, who found no infection and four tumors (benign or malignant) in 265 children with back pain, although some children with these conditions might have been diagnosed by the primary clinician and therefore not referred [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/14\">",
"     14",
"    </a>",
"    ]. No data exist on the distribution of diagnoses in children with prolonged back pain seen by the primary care clinician. However, a survey of schoolchildren aged 11 to 14 years found that, among the 25 percent of children with back pain at initial evaluation, up to one-quarter also had pain at reevaluation one and four years later, suggesting that persistent pain is not seen only in the presence of severe organic pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/5\">",
"     5",
"    </a>",
"    ]. Indeed, in this series, predictors of persistent pain were peer problems, short stature, and the presence of pain extending to multiple areas beyond the back.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical examination are central to the evaluation of the child with back pain. The initial history should focus on ruling out symptoms that suggest the presence of a serious underlying condition, such as infection or malignancy (",
"    <a class=\"graphic graphic_table graphicRef77644 \" href=\"UTD.htm?18/26/18859\">",
"     table 2",
"    </a>",
"    ). Subsequently, the most important elements of the history are in the characterization of the presenting pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathologic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Red flags\" that should alert the clinician to possible serious underlying pathology include young age (particularly younger than four years), fever, weight loss, severe or constant pain, nocturnal pain, progression over the course of time, history of acute or repetitive trauma, history of malignancy or tuberculosis exposure, evidence of neurologic dysfunction (eg, bowel or bladder dysfunction or abnormal reflexes), and interference with activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Pain that radiates down below the buttocks may indicate nerve root compression, but irritation of paraspinous structures also can radiate in this manner [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pain characterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is characterized in terms of quality, location and radiation, and exacerbating or relieving factors and activities. Asking the following questions will help to characterize the child's pain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What is the exact location of the pain?",
"     </li>",
"     <li>",
"      When and how did the symptoms begin?",
"     </li>",
"     <li>",
"      When does it hurt?",
"     </li>",
"     <li>",
"      What makes the pain better or worse?",
"     </li>",
"     <li>",
"      Does the back feel stiff in the morning or after rest?",
"     </li>",
"     <li>",
"      Does the pain interfere with activity?",
"     </li>",
"     <li>",
"      If the child participates in sports, how does he or she train?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The various causes of back pain in children have different clinical manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19162?source=see_link\">",
"     \"Back pain in children and adolescents: Overview of causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Simple sprains and strains typically present with nonspecific pain in the lower back that may radiate into one or both buttocks.",
"     </li>",
"     <li>",
"      Nerve root pain usually is brief; sharp and shooting; often increased by coughing or straining, standing or sitting; and usually relieved by lying down (",
"      <a class=\"graphic graphic_table graphicRef54497 \" href=\"UTD.htm?13/52/14155\">",
"       table 3",
"      </a>",
"      ). In comparison, pain originating in the peripheral nerves or lumbosacral plexus tends to be described as burning, like pins and needles, and \"asleep\" or numb in quality; usually it is worse when the patient is lying in bed at night.",
"     </li>",
"     <li>",
"      Severe, constant back pain, persisting at night, suggests the presence of neoplasm, infection, or nerve root compression.",
"     </li>",
"     <li>",
"      In painful mononeuropathies and radiculopathies, the area of pain and sensory abnormality may extend beyond the known sensory distribution of the affected peripheral nerve or beyond the dermatome of the affected root or dorsal root ganglion, as in postherpetic neuralgia. This phenomenon has been attributed to central nervous system plasticity.",
"     </li>",
"     <li>",
"      Sciatica (pain radiating from the lower back down the leg in a dermatomal distribution) is the major historical finding in patients with a herniated disc. The classic features are aching pain in the buttock and paresthesias radiating into the posterior thigh and calf or into the posterior lateral thigh and lateral foreleg.",
"     </li>",
"     <li>",
"      Pain that radiates below the knee is more likely to indicate a true radiculopathy; a history of persistent leg numbness or weakness further increases the likelihood of neurologic involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pain that is relieved by NSAIDs can indicate osteoid osteoma or an inflammatory etiology [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of benign bone tumors in children and adolescents\", section on 'Osteoid osteoma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination of the child with back pain should include inspection, palpation, and range of motion of the spine; neuromotor examination; and general examination of the abdomen, hips, extremities, inguinal areas, and rectum (particularly if a cauda equina syndrome is suspected). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34280?source=see_link&amp;anchor=H2#H2\">",
"     \"The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes\", section on 'Back'",
"    </a>",
"    .) The physical examination, sometimes combined with urinalysis, often is sufficient to exclude nonspinal pathology. Signs of spinal pathology include postural shift of the trunk, neurologic abnormality, and limitation of motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The way the child moves, sits, and stands provides useful information [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posture alone may suggest a diagnosis (eg, kyphosis, scoliosis).",
"     </li>",
"     <li>",
"      Differences in shoulder height, scapular prominence, flank crease, and pelvic symmetry can indicate scoliosis or discrepancy in leg lengths.",
"     </li>",
"     <li>",
"      Midline skin lesions (eg, dimples, hemangioma, hair patches), cavus feet, or calf atrophy may indicate underlying spinal lesions.",
"     </li>",
"     <li>",
"      Cafe au lait spots, if present, may indicate neurofibromatosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"       \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Signs of muscle weakness include atrophy (indicated by asymmetry of calf and thigh measurements), fasciculations, and pelvic tilt (the \"bad\" side is down).",
"     </li>",
"     <li>",
"      Gait testing should include walking on heels and on toes; spasticity, ataxia, and instability suggest a neurologic problem. Refusal to walk may be seen with discitis.",
"     </li>",
"     <li>",
"      Involuntary knee flexion may occur in patients with radiculopathy because the flexion guards against root traction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation of the lower spine and paraspinal muscles may reveal tenderness, muscle spasms, and radiating pain. Lumbosacral tenderness may be present in spondylolisthesis and disc herniations. Thoracic tenderness often is present in Scheuermann kyphosis. A prominent spinous process may be palpable in children with spondylolisthesis. Tenderness over the sacroiliac joints may be seen in sacroiliitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Range of motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The range of motion of the spine should be assessed by asking the patient to touch his or her toes, extend the spine, and bend to the right and left.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limitations or asymmetry on forward bending may indicate spinal cord tumors, spondylolisthesis, disc herniations, or discitis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/22\">",
"       22",
"      </a>",
"      ]. However, many normal children are unable to reach their toes when they bend forward from the waist. Lumbar lordosis should reverse with forward bending.",
"     </li>",
"     <li>",
"      Pain with back hyperextension may indicate a stress reaction to the pars interarticularis (spondylolysis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the ipsilateral one-legged hyperextension test (",
"    <a class=\"graphic graphic_picture graphicRef78320 \" href=\"UTD.htm?42/14/43233\">",
"     picture 1",
"    </a>",
"    ), the patient stands on one leg and leans backward. Pain ipsilateral to the weight-bearing leg constitutes a positive test [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the sensitivity and specificity of this technique are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neurologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic examination of the child with back pain should include evaluation of deep tendon reflexes, strength, and distribution of sensory complaints. In addition, the straight leg raising (SLR) test should be performed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities of the knee and ankle reflexes may indicate nerve root impingement at L3-L4 and S1, respectively.",
"     </li>",
"     <li>",
"      Proximal lower-extremity muscle weakness should be evaluated by asking the patient to rise from a squatting position.",
"     </li>",
"     <li>",
"      Gastrocnemius strength (S1) is tested with repeated rising up on the toes.",
"     </li>",
"     <li>",
"      Ankle dorsiflexion weakness may be indicative of L4 or L5 nerve root involvement. Sciatic pain may be increased by testing foot dorsiflexion with the knee extended because knee extension may stretch the S1 or L5 root.",
"     </li>",
"     <li>",
"      Great toe extensor weakness is indicative of L5 nerve root involvement.",
"     </li>",
"     <li>",
"      Gluteus maximus weakness (S1) may cause one buttock to sag; gluteus medius weakness (L5) may cause a lurching or waddling (Trendelenburg) gait.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Muscles are innervated by more than one nerve root. As a result, total paralysis implies a lesion of multiple roots or of peripheral nerves. Atrophy rarely is seen. Severe atrophy, detected by circumferential measurement, should raise the suspicion of an extradural neoplasm.",
"   </p>",
"   <p>",
"    A dermatomal distribution of loss of pinprick and touch sensation indicates and localizes root involvement (",
"    <a class=\"graphic graphic_figure graphicRef50419 \" href=\"UTD.htm?10/36/10822\">",
"     figure 3",
"    </a>",
"    ). A single root lesion usually causes only mild hypalgesia because a wide overlap of root distributions exists. The examiner may not be able to detect any sensory deficit, even though the patient has sensory symptoms. The web space of the great toe is a good place to test L5 sensation, and the lateral malleolus and posterolateral foot can be used to test S1 sensation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Straight leg raising",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SLR test, which stretches the nerves, can detect impingement of the spinal roots by herniated discs (relatively rare until late adolescence), spondylolisthesis, or other lesions. SLR is performed with the patient lying flat on his or her back with the uninvolved foot resting on the table and the knee bent at 45 degrees. The involved leg is raised straight up, while the ankle is kept at 90 degrees of flexion and the knee is fully extended. This test also may be performed with the patient seated; the seated position reduces strain on the hamstrings, which may give a false positive test when performed in the supine position.",
"   </p>",
"   <p>",
"    A positive SLR test elicits pain radiating down the leg or into the buttock. This pain must be distinguished from discomfort from hamstring stretch. The pain usually is worsened by dorsiflexion at the ankle or pressure in the popliteal fossa, which stretches the tibial nerve. In adults, as a test for disc herniation, the SLR test has a sensitivity of about 0.80 (indicating relatively few false negative tests) and a specificity of about 0.40 (indicating many false positive tests) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, a negative SLR test renders a herniated disc unlikely, although its presence is nonspecific. Specificity increases if elevation of the contralateral leg also elicits symptoms down the involved side (the crossed straight leg raising test) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/25\">",
"     25",
"    </a>",
"    ]. In children, in whom the spectrum of disease is different, sensitivity and specificity of these tests have not been determined, but the SLR test remains a useful means to assess nerve root compression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory and radiologic evaluation of children and adolescents with back pain should be directed by the clinical findings. Children with a short duration of symptoms, preceding trauma of the back, a clear musculoskeletal precipitant, normal neurologic examination, and an otherwise benign appearance can be managed conservatively without laboratory or radiologic testing.",
"   </p>",
"   <p>",
"    Children with protracted pain or other \"red flags\" of underlying pathology warrant further evaluation (",
"    <a class=\"graphic graphic_table graphicRef77644 \" href=\"UTD.htm?18/26/18859\">",
"     table 2",
"    </a>",
"    ). The evaluation of an inflammatory condition usually includes a complete blood count (CBC) with differential, erythrocyte sedimentation rate (ESR), and, if considering an infectious process, a blood culture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19162?source=see_link\">",
"     \"Back pain in children and adolescents: Overview of causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rheumatologic assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HLA-B27 antigen is associated strongly with ankylosing spondylitis, reactive arthritis, and spondylitis related to psoriasis and inflammatory bowel disease, testing rarely is useful in practice. HLA-B27 is relatively common (7 to 10 percent in the Caucasian population and exceeding 25 percent in some Native American and Scandinavian groups), whereas inflammatory spondylitis is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Therefore, the large majority of HLA-B27-positive children with back pain will have a non-B27-associated cause. Because spondylitis can occur in the absence of HLA-B27, testing generally does not affect posttest probability of disease sufficiently to be helpful in diagnosis. Other common rheumatologic assays, such as rheumatoid factor, ANA, and Lyme serology, are similarly not usually indicated in the evaluation of children with back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RADIOLOGIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory and radiologic evaluation of children and adolescents with back pain should be directed by the clinical findings. Children with a short duration of symptoms, preceding trauma of the back, a clear musculoskeletal precipitant, normal neurologic examination, and an otherwise benign appearance can be managed conservatively without laboratory or radiologic testing.",
"   </p>",
"   <p>",
"    Children with protracted pain or other \"red flags\" of underlying pathology warrant further evaluation (",
"    <a class=\"graphic graphic_table graphicRef77644 \" href=\"UTD.htm?18/26/18859\">",
"     table 2",
"    </a>",
"    ). Plain radiographs of the spine should be obtained to exclude congenital or acquired bony pathology. As a general rule, AP and lateral films are adequate, although spondylolysis can escape detection on these views alone and may require an oblique view [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/29\">",
"     29",
"    </a>",
"    ]. The choice of imaging modality after plain radiographs depends upon the specific diagnostic concern as described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient with known malignancy or evolving neurologic examination needs urgent and precise anatomic definition, rendering magnetic resonance imaging (MRI) the test of choice. If cord compression by tumor is a clinical concern, the administration of intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      should be considered while awaiting MRI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link\">",
"       \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26970?source=see_link\">",
"       \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      MRI also can document nonbony spinal tumors, discitis, and sacroiliac (SI) joint inflammation.",
"     </li>",
"     <li>",
"      Computed tomography (CT) scan can best identify paraspinous and intraabdominal pathology.",
"     </li>",
"     <li>",
"      Bone scan detects osteomyelitis, discitis, and early stress reactions in the pars interarticularis in incipient spondylolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bone scan will",
"      <strong>",
"       not",
"      </strong>",
"      detect soft tissue tumors or infections that do not impinge on bone and thus is not always a definitive study in a child with an otherwise worrisome presentation (",
"      <a class=\"graphic graphic_table graphicRef77644 \" href=\"UTD.htm?18/26/18859\">",
"       table 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2679/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/51/22320?source=see_link\">",
"       \"Patient information: Back pain in children and adolescents (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient back pain is a relatively common occurrence in children, particularly after early adolescence. Back pain that persists or worsens over time deserves careful attention since it is often associated with serious underlying pathology. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial history should focus on symptoms suggestive of a serious underlying condition, such as infection or malignancy (",
"      <a class=\"graphic graphic_table graphicRef77644 \" href=\"UTD.htm?18/26/18859\">",
"       table 2",
"      </a>",
"      ). The subsequent history should focus on characterization of the pain. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination should include inspection, palpation, and range of motion of the spine; neuromotor examination; and general examination of the abdomen, hips, extremities, inguinal areas, and rectum. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The laboratory and radiologic evaluation of children and adolescents with back pain should be directed by the clinical findings. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Laboratory evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Radiologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/1\">",
"      Hakala P, Rimpel&auml; A, Salminen JJ, et al. Back, neck, and shoulder pain in Finnish adolescents: national cross sectional surveys. BMJ 2002; 325:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/2\">",
"      Jeffries LJ, Milanese SF, Grimmer-Somers KA. Epidemiology of adolescent spinal pain: a systematic overview of the research literature. Spine (Phila Pa 1976) 2007; 32:2630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/3\">",
"      Masiero S, Carraro E, Celia A, et al. Prevalence of nonspecific low back pain in schoolchildren aged between 13 and 15 years. Acta Paediatr 2008; 97:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/4\">",
"      Pellis&eacute; F, Balagu&eacute; F, Rajmil L, et al. Prevalence of low back pain and its effect on health-related quality of life in adolescents. Arch Pediatr Adolesc Med 2009; 163:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/5\">",
"      Jones GT, Macfarlane GJ. Predicting persistent low back pain in schoolchildren: a prospective cohort study. Arthritis Rheum 2009; 61:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/6\">",
"      Leboeuf-Yde C, Kyvik KO. At what age does low back pain become a common problem? A study of 29,424 individuals aged 12-41 years. Spine (Phila Pa 1976) 1998; 23:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/7\">",
"      Balagu&eacute; F, Skovron ML, Nordin M, et al. Low back pain in schoolchildren. A study of familial and psychological factors. Spine (Phila Pa 1976) 1995; 20:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/8\">",
"      Troussier B, Davoine P, de Gaudemaris R, et al. Back pain in school children. A study among 1178 pupils. Scand J Rehabil Med 1994; 26:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/9\">",
"      Selbst SM, Lavelle JM, Soyupak SK, Markowitz RI. Back pain in children who present to the emergency department. Clin Pediatr (Phila) 1999; 38:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/10\">",
"      Negrini S, Carabalona R, Sibilla P. Backpack as a daily load for schoolchildren. Lancet 1999; 354:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/11\">",
"      Mackenzie WG, Sampath JS, Kruse RW, Sheir-Neiss GJ. Backpacks in children. Clin Orthop Relat Res 2003; :78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/12\">",
"      Jones GT, Watson KD, Silman AJ, et al. Predictors of low back pain in British schoolchildren: a population-based prospective cohort study. Pediatrics 2003; 111:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/13\">",
"      Turner PG, Green JH, Galasko CS. Back pain in childhood. Spine (Phila Pa 1976) 1989; 14:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/14\">",
"      Combs JA, Caskey PM. Back pain in children and adolescents: a retrospective review of 648 patients. South Med J 1997; 90:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/15\">",
"      Feldman DS, Hedden DM, Wright JG. The use of bone scan to investigate back pain in children and adolescents. J Pediatr Orthop 2000; 20:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/16\">",
"      Hollingworth P. Back pain in children. Br J Rheumatol 1996; 35:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/17\">",
"      Kellgren, JH. On the distribution of pain arising from deep somatic structures with charts of segmental pain areas. Clin Sci 1939; 4:35.",
"     </a>",
"    </li>",
"    <li>",
"     Schnebel, BE. Spine. In: Care of the young athlete, Sullivan, JA, Anderson, SJ (Eds), American Academy of Orthopedic Surgeons and American Academy of Pediatrics 2000. p.287.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/19\">",
"      King HA. Back pain in children. Orthop Clin North Am 1999; 30:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/20\">",
"      Acute low back problems in adults: assessment and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin 1994; :iii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/21\">",
"      Beattie PF, Meyers SP, Stratford P, et al. Associations between patient report of symptoms and anatomic impairment visible on lumbar magnetic resonance imaging. Spine (Phila Pa 1976) 2000; 25:819.",
"     </a>",
"    </li>",
"    <li>",
"     Staheli, LT. Spine and pelvis. In: Fundamentals of Pediatric Orthopedics, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.231.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/23\">",
"      Jackson DW, Wiltse LL, Dingeman RD, Hayes M. Stress reactions involving the pars interarticularis in young athletes. Am J Sports Med 1981; 9:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/24\">",
"      Masci L, Pike J, Malara F, et al. Use of the one-legged hyperextension test and magnetic resonance imaging in the diagnosis of active spondylolysis. Br J Sports Med 2006; 40:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/25\">",
"      Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA 1992; 268:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/26\">",
"      Gran JT, Husby G. HLA-B27 and spondyloarthropathy: value for early diagnosis? J Med Genet 1995; 32:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/27\">",
"      Reveille JD. HLA-B27 and the seronegative spondyloarthropathies. Am J Med Sci 1998; 316:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/28\">",
"      McGhee JL, Burks FN, Sheckels JL, Jarvis JN. Identifying children with chronic arthritis based on chief complaints: absence of predictive value for musculoskeletal pain as an indicator of rheumatic disease in children. Pediatrics 2002; 110:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/29\">",
"      Gehweiler JA Jr, Daffner RH. Low back pain: the controversy of radiologic evaluation. AJR Am J Roentgenol 1983; 140:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2679/abstract/30\">",
"      Kujala UM, Kinnunen J, Helenius P, et al. Prolonged low-back pain in young athletes: a prospective case series study of findings and prognosis. Eur Spine J 1999; 8:480.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2853 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_39_2679=[""].join("\n");
var outline_f2_39_2679=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathologic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pain characterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Inspection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Range of motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neurologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Straight leg raising",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rheumatologic assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RADIOLOGIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2853\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2853|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/42/5806\" title=\"figure 1\">",
"      Cumulative incidence back pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/44/18125\" title=\"figure 2\">",
"      Point prevalence back pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/36/10822\" title=\"figure 3\">",
"      Lumbosacral dermatomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2853|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/14/43233\" title=\"picture 1\">",
"      One-legged hyperextension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2853|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/40/12941\" title=\"table 1\">",
"      Causes of back pain in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/26/18859\" title=\"table 2\">",
"      Warning signs for serious causes of back pain in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/52/14155\" title=\"table 3\">",
"      Root versus nerve pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19162?source=related_link\">",
"      Back pain in children and adolescents: Overview of causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/51/22320?source=related_link\">",
"      Patient information: Back pain in children and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34280?source=related_link\">",
"      The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26970?source=related_link\">",
"      Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_39_2680="Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use";
var content_f2_39_2680=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/39/2680/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/39/2680/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/39/2680/contributors\">",
"     Marc A Pfeffer, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/39/2680/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/39/2680/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/39/2680/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/39/2680/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/39/2680/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blockade of the renin-angiotensin-aldosterone system (RAAS) is a key component of treatment of patients with systolic heart failure (HF) (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/1\">",
"     1",
"    </a>",
"    ]. RAAS blockade with angiotensin converting (ACE) inhibitor, angiotensin II receptor blocker (ARB), or aldosterone antagonist improves morbidity and mortality in these patients. The benefits of beta blockers are additive to those with RAAS agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss the clinical evidence on and use of ARBs in patients with HF. The mechanisms of action of these drugs in HF and the role of ACE inhibitors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The angiotensin II receptor blockers (ARBs) act by a different mechanism from ACE inhibitors, although both reduce the stimulation of angiotensin II receptors (",
"    <a class=\"graphic graphic_figure graphicRef55726 \" href=\"UTD.htm?9/23/9597\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19685?source=see_link\">",
"     \"Differences between angiotensin converting enzyme inhibitors and receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ACE inhibitors block the formation of angiotensin II, thereby decreasing the amount of angiotensin available to both AT1 and AT2 receptors.",
"     </li>",
"     <li>",
"      ARBs selectively block the binding of angiotensin II to the AT1 receptor, but do not affect the AT2 receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/2\">",
"       2",
"      </a>",
"      ]. The clinical importance of this is uncertain, since the AT1 receptor seems to dominate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=see_link\">",
"       \"Actions of angiotensin II on the heart\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another difference is that ACE inhibitors, but not ARBs, reduce kinin degradation, since ACE is also a kininase (",
"    <a class=\"graphic graphic_figure graphicRef55726 \" href=\"UTD.htm?9/23/9597\">",
"     figure 1",
"    </a>",
"    ). The accumulation of kinins may mediate some of the benefits as well as the adverse effects of ACE inhibitors. One important clinical consequence resulting from the lack of kinin accumulation is that the ARBs do not induce cough, a complication that occurs in 3 to 20 percent of patients treated with ACE inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS OF ARBS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with HF, ARBs have been evaluated in four settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In patients intolerant of ACE inhibitors",
"     </li>",
"     <li>",
"      As primary therapy in place of an ACE inhibitor",
"     </li>",
"     <li>",
"      As add-on therapy in patients treated with an ACE inhibitor",
"     </li>",
"     <li>",
"      In patients with preserved LVEF",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first three settings are discussed below. ARB use in patients with HF with preserved LVEF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment and prognosis of diastolic heart failure\", section on 'Angiotensin II receptor blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Comparison to placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benefits and harms of ARB therapy for heart failure were evaluated by a 2012 Cochrane review that included 22 studies in 17,900 patients with an LVEF &le;40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/3\">",
"     3",
"    </a>",
"    ]. The following findings were noted in trials comparing ARB therapy (without background ACE inhibitor therapy) to placebo:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nine trials (N = 4643) reported total mortality. ARBs appeared to reduce total mortality, although the result was of borderline statistical significance (RR 0.87, 95% CI 0.76-1.00). This estimate included two unpublished studies that were summarized in a meta-analysis sponsored by the manufacturer of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/4\">",
"       4",
"      </a>",
"      ]. An analysis limited to the seven fully reported trials found a smaller reduction in mortality that was again of borderline statistical significance (RR 0.91, CI 0.79-1.04).",
"      <br/>",
"      <br/>",
"      There was a statistically nonsignificant trend toward reduced cardiovascular mortality with ARB therapy (RR 0.88, 95% CI 0.75-1.03).",
"     </li>",
"     <li>",
"      Two trials reported rates of myocardial infarction and stroke with results largely reflecting the CHARM-Alternative trial results. Compared to placebo,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"       candesartan",
"      </a>",
"      had no effect on stroke but increased the risk of myocardial infarction (RR 1.44, 95% CI 1.03-2.01).",
"     </li>",
"     <li>",
"      The CHARM-Alternative trial contributed most of the data on hospitalizations [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/5\">",
"       5",
"      </a>",
"      ]. Although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"       candesartan",
"      </a>",
"      reduced hospitalizations for heart failure (RR 0.71, 95% CI 0.61-0.82), it increased the risk of hospital admissions for other causes (RR 1.12, 95% CI 1.00-1.25) and total hospitalizations were not significantly reduced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     In comparison to ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitor therapy reduces mortality in patients with systolic heart failure (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    ). As noted above, ACE inhibitors and ARBs have differing mechanisms of action (",
"    <a class=\"graphic graphic_figure graphicRef55726 \" href=\"UTD.htm?9/23/9597\">",
"     figure 1",
"    </a>",
"    ) and thus might be expected to differ in their clinical effects. However, relatively short-term studies have shown a number of similarities between the ARBs and ACE inhibitors with respect to exercise capacity, clinical status, neurohumoral activation, LVEF, and hemodynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 2012 Cochrane review, pooled results of trials comparing ARBs with ACE inhibitors in patients with HF with LVEF &le;40 percent showed no significant difference in mortality although the point estimate favored ACE inhibitor therapy (RR 1.05; 95% CI 0.91-1.22). There were also no significant differences in stroke, myocardial infarction, total hospitalizations or hospitalizations for HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/3\">",
"     3",
"    </a>",
"    ]. Drug withdrawals due to adverse effects were significantly less common with ARBs compared to ACE inhibitors (RR 0.63, 95% CI 0.52, 0.76). &nbsp;",
"   </p>",
"   <p>",
"    As noted above, the review also noted that in this population, ARBs had a borderline statistically significant effect on total mortality compared to placebo (RR 0.87, 95% CI, 0.76-1.0). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Comparison to placebo'",
"    </a>",
"    above.) This result appears to differ from the established beneficial effect on mortality of ACE inhibitor therapy in patients with LVEF &lt;40 percent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical HF (OR 0.80, 95% CI 0.74-0.87) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link&amp;anchor=H3#H3\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\", section on 'General efficacy'",
"    </a>",
"    .) This apparent inconsistency is likely due to the effect of chance (since comparison of mortality between ACE inhibitor and ARB therapy showed a nonsignificant trend favoring ACE inhibitors). Other possible explanations include inadequate ARB doses in the comparison trials and differences in clinical trial populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     In addition to ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed below, clinical trials have demonstrated that addition of an ARB to treatment with an ACE inhibitor improves clinical outcomes in selected patients with heart failure (CHARM-ADDED). Based on this evidence, some major society guidelines have suggested or recommended the addition of an ARB, if tolerated, to a regimen including ACE inhibitors and beta blockers in patients with persistent NYHA class II to III HF if the patient has normal renal function and low to normal serum potassium.",
"   </p>",
"   <p>",
"    However, based on the RALES, EPHESUS and EMPHASIS-HF results, we now recommend the addition of an aldosterone antagonist (rather than addition of an ARB) to the combination of an ACE inhibitor and beta blocker in patients who have NYHA class II HF and LVEF &le;30 percent; or NYHA class III to IV HF and an LVEF &lt;35 percent; or are post ST elevation MI with an LVEF &le;40 percent and have either symptomatic heart failure or diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link&amp;anchor=H15#H15\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Our approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although ACE inhibitors improve LV function and survival in patients with HF, alternative enzymatic pathways exist for the local production of angiotensin II within the myocardium (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=see_link&amp;anchor=H18#H18\">",
"     \"Actions of angiotensin II on the heart\", section on 'Cardiac renin-angiotensin-aldosterone system'",
"    </a>",
"    ). Increased activity of these local pathways, which are independent of angiotensin converting enzyme and not blocked by ACE inhibitors, may lead to increased production of angiotensin II. In addition, patients on chronic ACE inhibitor therapy often have a substantial rise in plasma renin activity and a gradual increase in ACE activity over time, resulting in reactivation of vascular tissue angiotensin II formation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations provide the rationale for combined treatment with an ACE inhibitor and an ARB, since the effect of increased angiotensin II formation can be blocked by the ARB. This approach has been evaluated in several randomized controlled trials. Although RESOLVD was the first such trial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/11\">",
"     11",
"    </a>",
"    ], both Val-HeFT and CHARM-Added were much larger and had much longer follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4526290\">",
"    <span class=\"h3\">",
"     Meta-analysis of ARB plus ACE inhibitor versus ACE inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Cochrane review of outcomes of ARB plus ACE inhibitor therapy to ACE inhibitor therapy alone in patients with HF was dominated by the Val-HeFT and CHARM-Added results [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/3,12,13\">",
"     3,12,13",
"    </a>",
"    ]. There were no statistically significant differences in total mortality (RR 0.98, 0.90-1.06), cardiovascular mortality, or non-cardiovascular mortality between combined ARB plus ACE inhibitor and ACE inhibitor monotherapy. Combination therapy reduced hospitalization for HF compared to ACE inhibitor therapy (RR 0.81, 95% CI .074, 0.89) but did not reduce total hospitalizations. Withdrawals due to adverse effects were more frequent with combination therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     In acute MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the VALIANT trial, patients within 10 days of an acute MI complicated by LV dysfunction and or heart failure were randomly assigned to treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , or both [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/14\">",
"     14",
"    </a>",
"    ]. Although there was no difference in the incidence of primary end point of death from any cause among the three groups, adverse events were more common in patients on combination therapy. Thus, combination therapy should not be initiated immediately after an acute MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Combination with a beta blocker",
"    </span>",
"    &nbsp;&mdash;&nbsp;Val-HeFT and CHARM-Added provided conflicting data on the impact of adding an ARB to an ACE inhibitor in patients treated with a beta blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In Val-HeFT, the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    in such patients was associated with increased mortality and a trend toward an increase in the combined end point of mortality and morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/12\">",
"     12",
"    </a>",
"    ]. In contrast, in CHARM-Added in which a greater proportion were treated with a beta blocker, an interaction analysis indicated that the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    was not influenced by whether or not the subject was taking a beta blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Combination with aldosterone antagonist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine use of the combination of an ACE inhibitor, an ARB, and an aldosterone antagonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ) is",
"    <strong>",
"     not",
"    </strong>",
"    generally recommended in the treatment of HF because of concerns about hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently the EMPHASIS-HF trial demonstrated the efficacy of the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    (to ACE inhibitor and beta blocker therapy) in patients with class II or III HF and left ventricular ejection fraction &le;30 percent in reducing the risk of death and the risk of hospitalization for HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link&amp;anchor=H1107515#H1107515\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Eplerenone in EMPHASIS-HF trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although US major society guidelines have not yet addressed the EMPHASIS-HF trial, current evidence supports the use of the combination of aldosterone antagonist (rather than an ARB) and ACE inhibitor (along with beta blocker therapy) in patients who have NYHA class II HF and LVEF &le;30; as well as in patients who have NYHA class III to IV HF with LVEF &lt;35 percent; as well as in patients post ST elevation MI with an LVEF &le;40 percent and either symptomatic heart failure or diabetes mellitus.",
"   </p>",
"   <p>",
"    In patients receiving a beta blocker, an ACE inhibitor, and an aldosterone antagonist, addition of an ARB may be considered in selected patients with refractory HF after confirming that the patient can tolerate the first three drugs. However, there are important safety concerns and efficacy has",
"    <strong>",
"     not",
"    </strong>",
"    been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients receiving any regimen including one or more inhibitors of the renin-angiotensin-aldosterone system, precautions should be taken to avoid hyperkalemia including careful screening of patients for baseline renal dysfunction or hyperkalemia and close monitoring of renal function and serum potassium concentration during adjustment of either regimen. A specific approach to minimizing the risk of hyperkalemia has been proposed (",
"    <a class=\"graphic graphic_table graphicRef67783 \" href=\"UTD.htm?31/16/32011\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link&amp;anchor=H8#H8\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Risk of hyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Potential side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of randomized controlled trials of combination ARB and ACE inhibitor therapy found that such therapy was associated with significant increases in adverse effects in chronic HF patients including hyperkalemia, worsening renal function, symptomatic hypotension, and an increased frequency of medication discontinuation compared to control therapy that included only one of the therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25855302\">",
"    <span class=\"h2\">",
"     Symptomatic benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;An analysis of data from the CHARM program (including CHARM-Alternative and CHARM-Added trials) demonstrated a beneficial impact on NYHA functional class at 38 months in those randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    (n=3803) compared to placebo (n=3796). No heterogeneity in symptomatic response between the CHARM trials was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, a study of 5010 Val-HeFT participants demonstrated greater improvement in signs and symptoms with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     AGENT AND DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data from CHARM-Added and Val-HeFT demonstrate that either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    (starting at 4 to 8 mg daily, titrated to a target dose of 32 mg daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    (starting at 20 to 40 mg twice daily, titrated to a target dose of 160 mg twice daily) is effective in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High dose (150 mg)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    may provide some benefit although direct comparison to ACE inhibitor therapy is lacking. The only dosing regimen directly compared to ACE inhibitor (losartan 50 mg daily in ELITE II) was not as effective as ACE inhibitor therapy.",
"   </p>",
"   <p>",
"    In the HEAAL trial, slightly but significantly better outcomes were obtained with 150 mg versus 50 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    in 3846 ACE intolerant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/21\">",
"     21",
"    </a>",
"    ]. At a median follow-up of 4.7 years, patients assigned to the 150 mg group had a significantly lower incidence of the primary end point of cardiovascular death or hospitalization for HF (43 versus 46 percent; adjusted hazard ratio 0.90, 95% CI 0.82-0.99) and of hospitalization for HF (23 versus 26 percent). Renal dysfunction, hypotension, and hyperkalemia were more common in the 150 mg than in the 50 mg group, but rates of treatment discontinuation were similar in the two groups.",
"   </p>",
"   <p>",
"    Thus, the evidence is strongest for use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    , as compared to other ARBs, in the treatment of HF with reduced LVEF. An observational study of over 30,000 patients in the Swedish Heart Failure Registry found a lower mortality risk with use of candesartan compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    (adjusted HR 1.43; 95% CI, 1.23-1.65) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/22\">",
"     22",
"    </a>",
"    ]. This difference was observed with both an LVEF less than 40 percent and with an LVEF of 40 percent or more.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS BY MAJOR SOCIETIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the use of ARBs in patients with chronic HF were outlined in the 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines, the 2006 Heart Failure Society of America guidelines, and the 2008 European Society of Cardiology (ESC) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/1,23,24\">",
"     1,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     ACC/AHA and HFSA guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally agree with the 2005 (with 2009 focused update)",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    heart failure guideline recommendations for use of ARBs (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/1\">",
"     1",
"    </a>",
"    ]. Similar recommendations were included in the 2010 HFSA guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ARB therapy is recommended in patients with current or prior symptoms of HF and reduced LVEF who are intolerant of ACE inhibitors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted in the 2010 HFSA guidelines, this recommendation applies only when the ACE inhibitor intolerance is",
"    <strong>",
"     not",
"    </strong>",
"    hyperkalemia or renal insufficiency. In addition, the HFSA guidelines recommend that ARBs should be considered in patients experiencing angioedema while on ACE inhibitors based on their underlying risk and recognizing that angioedema has been reported infrequently with ARBs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines had suggested the use of ARBs as a reasonable alternative to ACE inhibitors as first-line therapy for patients with mild to moderate HF and reduced LVEF, particularly in patients taking an ARB for another indication. The HFSA guidelines suggested that an ARB may be considered as initial therapy rather than an ACE inhibitor for HF post-myocardial infarction or for chronic systolic HF.",
"      <br/>",
"      <br/>",
"      However, given the evidence of greater survival benefit from ACE inhibitor therapy in patients with systolic HF, we prefer ACE inhibitor rather than ARB therapy as a first-line agent in such patients. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'In comparison to ACE inhibitors'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      The HFSA guidelines suggested that addition of an ARB may be considered in persistently symptomatic patients with reduced LVEF who are already being treated with conventional therapy. The guidelines noted that routine administration of an ARB is",
"      <strong>",
"       not",
"      </strong>",
"      recommended in addition to an ACE inhibitor and beta-blocker therapy in patients with a recent acute MI and LV dysfunction.",
"      <br/>",
"      <br/>",
"      However, the EMPHASIS-HF trial was published after the",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      and HFSA guidelines, and the combined evidence from clinical trials now supports the addition of aldosterone antagonist (rather than an ARB) to ACE inhibitor and beta blocker therapy in patients with symptomatic HF. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'In addition to ACE inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine combined use of an ARB, an ACE inhibitor and an aldosterone antagonist is",
"      <strong>",
"       not",
"      </strong>",
"      recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     ESC guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2012 ESC guidelines included the following recommendations with regard to ARBs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2680/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ARB therapy is recommended in patients with HF with LVEF &le;40 percent who are unable to tolerate an ACE inhibitor because of cough.",
"     </li>",
"     <li>",
"      ARB therapy is also recommended in patients with an LVEF &le;40 percent who remain symptomatic (NYHA functional class II to IV) despite optimal treatment with an ACE inhibitor and beta-blocker who are unable to tolerate an aldosterone antagonist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In selected patients with heart failure (HF) due to systolic dysfunction, ARB therapy reduces hospitalizations for HF and produces a borderline statistically significant reduction in mortality. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical trials of ARBs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25855302\">",
"       'Symptomatic benefit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two settings in which ARBs might be used in patients with HF:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients intolerant of ACE inhibitors (for which data are firmest)",
"     </li>",
"     <li>",
"      In combination with ACE inhibitors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Our approach differs slightly from the major society guidelines in that the guidelines regard all ARBs as having a common class effect while we recommend specific drugs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"       candesartan",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"       valsartan",
"      </a>",
"      ) based on the availability of direct evidence from clinical trials.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When using an ARB, we prefer either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"       candesartan",
"      </a>",
"      (starting at 4 to 8 mg daily, titrated to a target dose of 32 mg daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"       valsartan",
"      </a>",
"      (starting at 20 to 40 mg twice daily, titrated to a target dose of 160 mg twice daily), which have been most studied, as opposed to other ARBs. Observational data suggested lower mortality risk with candesartan as compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      . If losartan is being used, a dose of 50 mg should not be considered effective. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Agent and dose'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that ARBs be used in patients with HF due to systolic dysfunction who are intolerant of ACE inhibitors for reasons other than renal dysfunction or hyperkalemia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The ARB is most likely to be tolerated in patients who had cough or angioedema on an ACE inhibitor. In contrast, renal dysfunction, hyperkalemia, and hypotension are likely to recur. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Comparison to placebo'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evidence for use of ARBs in combination with ACE inhibitors is more limited. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'In addition to ACE inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Some major society guidelines have suggested the addition of an ARB, if tolerated, to a regimen including ACE inhibitors and beta blockers in patients with persistent NYHA class II to III HF if the patient has normal renal function and low to normal serum potassium. However, the results of the EMPHASIS-HF trial support the use of aldosterone antagonist (rather than an ARB) in addition to ACE-I and beta-blocker therapy in patients who have NYHA functional class II or III HF and an LVEF &le;30 percent.",
"      <br/>",
"      <br/>",
"      Thus, we now recommend aldosterone antagonist therapy (rather than ARB therapy) in addition to ACE inhibitor and beta blocker therapy to treat HF in patients who have NYHA functional class II HF and an LVEF &le;30 percent; or NYHA functional class III to IV HF and an LVEF &lt;35 percent; or who are post ST elevation MI who are already receiving therapeutic doses of ACE inhibitor, have an LVEF &le;40 percent, and have either symptomatic heart failure or diabetes mellitus, who can be carefully monitored for serum potassium and renal function. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'In addition to ACE inhibitors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link\">",
"       \"Use of aldosterone antagonists in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that an ARB",
"      <strong>",
"       not",
"      </strong>",
"      be added to an ACE inhibitor in the immediate post-MI setting (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'In acute MI'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/1\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/2\">",
"      Goldsmith DJ. Angiotensin receptor antagonists. Lancet 1997; 349:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/3\">",
"      Heran BS, Musini VM, Bassett K, et al. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev 2012; 4:CD003040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/4\">",
"      Sharma D, Buyse M, Pitt B, Rucinska EJ. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group. Am J Cardiol 2000; 85:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/5\">",
"      Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/6\">",
"      Guazzi M, Melzi G, Agostoni P. Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 80:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/7\">",
"      Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995; 26:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/8\">",
"      Lang RM, Elkayam U, Yellen LG, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. J Am Coll Cardiol 1997; 30:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/9\">",
"      Flather MD, Yusuf S, K&oslash;ber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/10\">",
"      Farquharson CA, Struthers AD. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/11\">",
"      McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/12\">",
"      Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/13\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/14\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/15\">",
"      Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/16\">",
"      Weir RA, McMurray JJ, Puu M, et al. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail 2008; 10:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/17\">",
"      Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/18\">",
"      Phillips CO, Kashani A, Ko DK, et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007; 167:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/19\">",
"      O'Meara E, Solomon S, McMurray J, et al. Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2004; 25:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/20\">",
"      Wong M, Staszewsky L, Carretta E, et al. Signs and symptoms in chronic heart failure: relevance of clinical trial results to point of care-data from Val-HeFT. Eur J Heart Fail 2006; 8:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/21\">",
"      Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/22\">",
"      Eklind-Cervenka M, Benson L, Dahlstr&ouml;m U, et al. Association of candesartan vs losartan with all-cause mortality in patients with heart failure. JAMA 2011; 305:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/23\">",
"      . Heart failure in patients with left ventricular systolic dysfunction. J Card Fail 2006; 12:e38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/24\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/25\">",
"      Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2680/abstract/26\">",
"      McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33:1787.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3482 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-537ACF1ECA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_39_2680=[""].join("\n");
var outline_f2_39_2680=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL TRIALS OF ARBS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Comparison to placebo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      In comparison to ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      In addition to ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Rationale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4526290\">",
"      - Meta-analysis of ARB plus ACE inhibitor versus ACE inhibitor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - In acute MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Combination with a beta blocker",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Combination with aldosterone antagonist",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Potential side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25855302\">",
"      Symptomatic benefit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      AGENT AND DOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RECOMMENDATIONS BY MAJOR SOCIETIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ACC/AHA and HFSA guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ESC guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3482\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3482|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/23/9597\" title=\"figure 1\">",
"      Comparison of the actions of ACE inhibitors and ARBs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3482|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/1/40989\" title=\"table 1\">",
"      ACC AHA Rx systolic HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/16/32011\" title=\"table 2\">",
"      Approach high K RAAS blockers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19685?source=related_link\">",
"      Differences between angiotensin converting enzyme inhibitors and receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_39_2681="Interstitial pneumonitis in RA";
var content_f2_39_2681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 600px\">",
"   <div class=\"ttl\">",
"    Interstitial pneumonitis in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 580px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stages of interstitial pneumonitis in rheumatoid arthritis. Left panel: The histopathologic finding of permeation of the interaveolar septae by a lymphocytic infiltrate is consistent with lymphocytic interstitial pneumonitis in rheumatoid arthritis. Right panel: A more advanced stage of lymphocytic interstitial pneumonitis reveals germinal center formation and a focus of angiocentric granulomatous inflammation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_39_2681=[""].join("\n");
var outline_f2_39_2681=null;
var title_f2_39_2682="Clinical features and detection of congenital hypothyroidism";
var content_f2_39_2682=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and detection of congenital hypothyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/39/2682/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/39/2682/contributors\">",
"     Stephen LaFranchi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/39/2682/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/39/2682/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/39/2682/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/39/2682/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/39/2682/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/39/2682/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital hypothyroidism, occurring in approximately 1:2000 to 1:4000 newborns, is one of the most common preventable causes of intellectual disability (mental retardation). There is an inverse relationship between age at clinical diagnosis and treatment initiation and intelligence quotient (IQ) later in life, so that the longer the condition goes undetected, the lower the IQ [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most newborn babies with congenital hypothyroidism have few or no clinical manifestations of thyroid hormone deficiency, and the majority of cases are sporadic. As a result, it is not possible to predict which infants are likely to be affected. For these reasons, newborn screening programs in which either thyroxine (T4) or thyrotropin (TSH) are measured in heel-stick blood specimens were developed in the mid-1970s to detect this condition as early as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/2\">",
"     2",
"    </a>",
"    ]. These screening efforts have been largely successful, but more severely affected infants may still have a slightly reduced IQ and other neurologic deficits despite prompt diagnosis and initiation of therapy.",
"   </p>",
"   <p>",
"    This topic will review the epidemiology, causes, clinical manifestations, and diagnosis of congenital hypothyroidism, and its detection by newborn screening. Treatment and prognosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15081?source=see_link\">",
"     \"Treatment and prognosis of congenital hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data obtained from national and regional screening programs indicate that the incidence of congenital hypothyroidism varies globally. The incidence varies by geographic location and by ethnicity, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study over a 20-year period (1981 to 2002) from a French screening program, the incidence of permanent congenital hypothyroidism was 1:4000 [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study in the Greek Cypriot population over an 11-year period (1990 to 2000), the incidence of permanent congenital hypothyroidism was 1:1800. Hypothyroidism was initially detected by an elevated TSH value obtained between 3 to 6 days of age [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A summary of all screening programs in the United States found that the incidence of congenital hypothyroidism increased from 1:4094 in 1987 to 1:2372 in 2002 [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/5\">",
"       5",
"      </a>",
"      ]. The reason for the increased incidence is not clear. It is possible that changes in testing cutoffs have led to detection of milder cases. In addition, there is some variation in the incidence among different racial and ethnic groups, and the mix of these groups has changed. A review of the New York program during the years 2000 to 2003 showed that the incidence of congenital hypothyroidism was somewhat lower in white (1:1815) and black infants (1:1902), as compared to Hispanic (1:1559) and Asian infants (1:1016); the overall incidence of congenital hypothyroidism was 1:1601 [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/5\">",
"       5",
"      </a>",
"      ]. In addition, the incidence was nearly double in twin births (1:876) as compared to singletons (1:1765), and even higher in multiple births (1:575). The incidence was higher in preterm infants (&lt;1500 gm; 1:1396) than term infants (&gt;2500 gm 1:1843). Older mothers (&gt;39 years of age) had a higher incidence (1:1328) than younger mothers (&lt;20 years; 1:1703).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nearly all screening programs report a female preponderance, approaching a 2:1 female to male ratio. A report from Quebec shows that this female preponderance occurs mostly with thyroid ectopy, and less so with agenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/6\">",
"     6",
"    </a>",
"    ]. Another study from Quebec found that thyroid dysgenesis was more prevalent in white than in black infants, whereas dyshormonogenesis occurred equally in these racial groups [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Thyroid dysgenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 85 percent of permanent cases of congenital hypothyroidism are sporadic (most caused by thyroid dysgenesis) and 15 percent are hereditary (most caused by one of the inborn errors of thyroid hormone synthesis) (",
"    <a class=\"graphic graphic_table graphicRef68356 \" href=\"UTD.htm?34/29/35292\">",
"     table 1",
"    </a>",
"    ). As noted above, the apparent increasing incidence of congenital hypothyroidism is likely due to the detection of milder cases, including cases of subclinical hypothyroidism and transient hypothyroidism. In a study from Japan, patients with hypothyroidism detected by newborn screening were reevaluated at ages 5 to 19 years. Among the cases with overt hypothyroidism, 73 percent were caused by thyroid dysgenesis, whereas of cases of subclinical hypothyroidism, only 36 percent were caused by thyroid dysgenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, some of these disorders may present after the neonatal period and are sometimes called &ldquo;late-onset congenital hypothyroidism&rdquo;. Late-onset disease is most often caused by one of the inborn errors of thyroxine synthesis or an ectopic thyroid gland. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=see_link&amp;anchor=H14#H14\">",
"     \"Acquired hypothyroidism in childhood and adolescence\", section on 'Late-onset congenital hypothyroidism'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6\">",
"     'Disorders of thyroid hormone synthesis and secretion'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7\">",
"     'Defects in thyroid hormone transport'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Thyroid dysgenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of congenital hypothyroidism is some form of thyroid dysgenesis, (eg, agenesis, hypoplasia, or ectopy). Thyroid ectopy accounts for two-thirds of the cases worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 230 infants with permanent primary hypothyroidism, representing 90 percent of all infants identified by newborn screening in Quebec from 1988 to 1997, 61 percent had ectopic thyroid tissue, 16 percent had thyroid agenesis, 4 percent had a normal-sized thyroid and 18 percent had a goiter, as determined by radionuclide imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/10\">",
"     10",
"    </a>",
"    ]. More girls than boys had thyroid ectopy (104 versus 37), but there were similar numbers of girls and boys in other groups. Among these infants, 5 percent had other congenital abnormalities, mostly cardiac septal defects. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Congenital malformations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although most cases of thyroid dysgenesis are sporadic, there is evidence of a",
"    <span class=\"nowrap\">",
"     familial/genetic",
"    </span>",
"    component in some patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 2472 patients with congenital hypothyroidism resulting from thyroid dysgenesis (identified by newborn screening in France between 1980 and 1998), 48 (2 percent) of cases appeared to be familial [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. The distribution of various causes of hypothyroidism in both the sporadic and familial groups was similar to that in the Quebec study.",
"     </li>",
"     <li>",
"      Further evidence of a genetic component comes from a study of 84 children with congenital hypothyroidism, whose first-degree relatives were more likely to have asymptomatic thyroid developmental abnormalities than controls (21.4 and 0.9 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/13\">",
"       13",
"      </a>",
"      ]. This suggests there is a common genetic component of congenital hypothyroidism with heterogeneous phenotypes. However, there was discordance for thyroid dysgenesis in all monozygotic twins (five pairs) and dizygotic twins (seven pairs) in both the Quebec and Brussels screening centers [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In rare cases, thyroid dysgenesis have been associated with loss-of-function mutations in PAX-8, thyroid transcription factor-2 (TTF-2, also called FOXE1), and transcription factors NKX2.1 (formerly called TTF-1) and NKX2.5 [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/15-19\">",
"       15-19",
"      </a>",
"      ]. A homozygous missense mutation in TTF-2 resulted not only in thyroid agenesis, but cleft palate in two male siblings [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/20\">",
"       20",
"      </a>",
"      ]. Not all TTF-2 mutations are associated with thyroid agenesis, as shown by a case report of a patient with congenital hypothyroidism and a TTF-2 mutation, associated with cleft palate, spiky hair, and bilateral choanal atresia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/21\">",
"       21",
"      </a>",
"      ]. Thyroid scan showed thyroid tissue in a eutopic location. NKX2.1 is expressed in both the thyroid and central nervous system. Mutations in NKX2.1 have been reported to result in congenital hypothyroidism with persistent neurologic problems, including ataxia, despite early thyroid hormone treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infants with trisomy 21 (Down syndrome) have a higher incidence of hypothyroidism detected by newborn screening programs. Whereas older children with trisomy 21 have autoimmune thyroid disease, the hypothyroidism seen in neonates is not associated with antithyroid antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/22\">",
"       22",
"      </a>",
"      ]. There is speculation that the extra chromosome 21 results in genomic dosage imbalance of dosage-sensitive genes interfering with thyroid hormone production.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Resistance to TSH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the TSH receptor will present as primary hypothyroidism, with an elevated serum TSH and low T4 level. Such defects are increasingly recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/23\">",
"     23",
"    </a>",
"    ]. In a report from Japan, TSH receptor mutations were present in 4.3 percent of patients with congenital hypothyroidism (1:118,000 of the general population) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/24\">",
"     24",
"    </a>",
"    ]. In a report from Great Britain, TSH receptor mutations were identified in 5 percent of children with congenital nongoitrous hypothyroidism born to consanguineous families [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, some forms of pseudohypoparathyroidism include congenital hypothyroidism. This is a result of G-protein alpha subunit (GNAS) gene mutations that interfere with both PTH and TSH signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/26\">",
"     26",
"    </a>",
"    ]. A complex phenotype of congenital hypothyroidism and pseudohypoparathyroidism has been described in the presence of a combination of inactivating mutations of the TSH receptor and mutations of the downstream G protein (GNAS) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=see_link&amp;anchor=H2#H2\">",
"     \"Resistance to thyrotropin and thyrotropin-releasing hormone\", section on 'Resistance to TSH (RTSH)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Disorders of thyroid hormone synthesis and secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary defects in virtually all steps in thyroid hormone biosynthesis and secretion have been described; all are characterized by autosomal recessive inheritance. Among them, the most common is a defect in thyroid peroxidase activity that results in impaired iodide oxidation and organification, and may be associated with sensory-neural hearing loss (Pendred syndrome) (",
"    <a class=\"graphic graphic_figure graphicRef76931 \" href=\"UTD.htm?26/29/27088\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24280?source=see_link&amp;anchor=H4#H4\">",
"     \"Congenital and acquired goiter in children\", section on 'Inborn errors of thyroid hormone production'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Other less common defects include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Defects in iodide transport, caused by a mutation in the",
"      <span class=\"nowrap\">",
"       sodium/iodide",
"      </span>",
"      symporter gene [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Defects in the generation of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      , a substrate for thyroid peroxidase in the oxidation of iodide, caused by mutations in the dual oxidase 2 gene (DUOX2, formerly called thyroid oxidase 2, THOX2) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/30,31\">",
"       30,31",
"      </a>",
"      ], or the related gene, dual oxidase maturation factor 2 (DUOXA2) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Production of abnormal thyroglobulin molecules, caused by mutations in the thyroglobulin gene [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Iodotyrosine deiodinase deficiency, due to homozygous mutations of the DEHAL1 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Altogether, these disorders account for approximately 15 percent of cases of congenital hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=see_link\">",
"     \"Thyroid hormone synthesis and physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Defects in thyroid hormone transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Passage of thyroid hormone into the cell is facilitated by plasma membrane transporters. A mutation in one such transporter gene, monocarboxylate transporter 8 (MCT8), located on the X chromosome, has been reported in more than 100 individuals with X-linked mental retardation. The defective transporter appears to impair passage of T3 into neurons; this syndrome is characterized by elevated serum T3 levels and psychomotor retardation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/35\">",
"     35",
"    </a>",
"    ]. This disorder is discussed in detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=see_link&amp;anchor=H17#H17\">",
"     \"Reduced sensitivity to thyroid hormone\", section on 'Thyroid hormone cell transporter defect'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22687023\">",
"    <span class=\"h2\">",
"     Defects in thyroid hormone metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited defects in thyroid hormone metabolism involve the gene for selenocysteine insertion sequence-binding protein 2 (SECISBP-2). In theory, mutations in this gene could cause congenital hypothyroidism, but to date there are only reports in children (with short stature and delayed bone age) and adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=see_link&amp;anchor=H23#H23\">",
"     \"Reduced sensitivity to thyroid hormone\", section on 'Thyroid hormone metabolism defect'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22687042\">",
"    <span class=\"h2\">",
"     Resistance to thyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to thyroid hormone is caused by mutations in thyroid hormone receptors (primarily the TH receptor beta gene). The incidence is approximately 1:40,000. It is characterized by high serum T4, free T4, T3, and free T3 levels with normal or slightly elevated serum TSH levels. Rarely, patients with high TSH levels may be detected by newborn screening programs. Patients generally do not have clinical manifestations of hyperthyroidism, and, for most, no treatment is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=see_link&amp;anchor=H4#H4\">",
"     \"Reduced sensitivity to thyroid hormone\", section on 'Resistance to thyroid hormone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Central hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with central (hypothalamic or pituitary) hypothyroidism are detected by screening programs that employ the initial",
"    <span class=\"nowrap\">",
"     T4/follow-up",
"    </span>",
"    TSH approach. Screening programs based only on TSH screening alone will not identify these infants. Central hypothyroidism occurs in 1:25,000 to 1:100,000 newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/36\">",
"     36",
"    </a>",
"    ]. It may be associated with other congenital syndromes, particularly mid-line defects such as septo-optic dysplasia or mid-line cleft lip and palate defects, and may follow birth trauma or asphyxia. Rare genetic causes result from mutations in the genes for the thyrotropin-releasing hormone receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/37\">",
"     37",
"    </a>",
"    ], or for TSH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Newborn screening programs'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=see_link\">",
"     \"Resistance to thyrotropin and thyrotropin-releasing hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most infants with central hypothyroidism, except those with mutations in the genes for TSH, TRH, or TRH receptors, have other pituitary hormone deficiencies. In a large prospective study, all infants with delayed TSH response to TRH had multiple pituitary hormone deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/40\">",
"     40",
"    </a>",
"    ]. The presence of another hormone deficiency should be particularly suspected in infants with hypoglycemia or micropenis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link\">",
"     \"Approach to hypoglycemia in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Congenital central hypothyroidism also can be caused by insufficient treatment of maternal hyperthyroidism during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Congenital central hypothyroidism may persist beyond 6 months of age especially when maternal thyrotoxicosis occurred before 32 weeks gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/42\">",
"     42",
"    </a>",
"    ]. One study suggests that some of these infants also may have primary hypothyroidism with thyroid \"disintegration\", possibly because insufficient TSH during the period of maternal hyperthyroidism inhibited the normal growth and development of the fetal thyroid [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Transient congenital hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient congenital hypothyroidism is more common in Europe (1:100) than in North America (1:50,000). In a 20-year study from a French newborn screening program, 40 percent of patients had transient hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/3\">",
"     3",
"    </a>",
"    ]. The causes of transient hypothyroidism in newborn infants are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Iodine deficiency &mdash; Iodine deficiency, particularly in preterm infants, accounts for many cases in Europe, where maternal dietary iodine intake is less than in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transfer of blocking antibodies or antithyroid drugs &mdash; Transplacental transfer of TSH-receptor blocking antibodies (TRB-Ab) can occur in infants of mothers with autoimmune thyroid disease [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/45\">",
"       45",
"      </a>",
"      ]. Such a diagnosis should also be considered if more than one infant born to the same mother (in the same or multiple pregnancies) is identified as having primary hypothyroidism by newborn screening. Studies using newborn screening specimens show TRB-Ab in approximately 1:100,000 newborns [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/46\">",
"       46",
"      </a>",
"      ]. This form of hypothyroidism usually subsides in one to three months as the maternal antibodies are cleared [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antithyroid drugs &mdash; Antithyroid drugs given to mothers with hyperthyroidism also can cross the placenta. These drugs are cleared in days; as a result, many of these infants are euthyroid when restudied a few weeks after delivery.",
"     </li>",
"     <li>",
"      Iodine exposure &mdash; Exposure of the fetus or newborn to high doses of iodine can cause hypothyroidism. This can occur in infants of mothers with cardiac arrhythmias treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/49\">",
"       49",
"      </a>",
"      ], when iodine-containing antiseptic compounds are used in mothers or infants, or after amniofetography with a radiographic contrast agent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. The risk is probably related to the type and duration of iodine exposure. Transient exposure of pregnant women to an iodinated contrast agent for computerized tomography study appears to have no effect on neonatal thyroid function [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20568?source=see_link\">",
"       \"Iodine-induced thyroid dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link&amp;anchor=H20#H20\">",
"       \"Diagnostic imaging procedures during pregnancy\", section on 'Iodinated contrast materials'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Large hepatic hemangiomas &mdash; Large hepatic hemangiomas, present from birth, may produce increased levels of type 3 deiodinase, resulting in \"consumptive hypothyroidism\". A case report describes an infant with a massive hepatic hemangioendothelioma that caused hypothyroidism, discovered at eight weeks of age [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/54\">",
"       54",
"      </a>",
"      ]. Large doses of thyroid hormone were required to normalize serum TSH. The hypothyroidism resolved by 16 months of age, as the hemangioendothelioma regressed.",
"     </li>",
"     <li>",
"      Mutations in the dual oxidase (DUOX1 and DUOX2) gene &mdash; The dual oxidase genes are involved in the generation of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      , required by thyroid peroxidase in the synthesis of thyroid hormone. Biallelic loss-of-function mutations in DUOX2 and monoallelic loss-of-function mutations in DUOXA1 genes are rare causes of transient congenital hypothyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. Mutations in the related gene DUOXA2 also are reported to cause a more permanent, albeit mild, form of congenital hypothyroidism, as discussed above. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Disorders of thyroid hormone synthesis and secretion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority (more than 95 percent) of infants with congenital hypothyroidism have few if any clinical manifestations of hypothyroidism at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/57\">",
"     57",
"    </a>",
"    ]. This is because some maternal T4 crosses the placenta, so that even in infants who cannot make any thyroid hormone, umbilical cord serum T4 concentrations are about 25 to 50 percent of those of normal infants [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/58\">",
"     58",
"    </a>",
"    ]. In addition, many infants with congenital hypothyroidism have some, albeit inadequate, functioning thyroid tissue. Despite these mitigating influences, congenital hypothyroidism may have subtle effects in utero. One report described reduced variability in fetal heart rate tracings in nearly 50 percent of infants with congenital hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Birth length and weight typically are within the normal range although birth weight can be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/60\">",
"     60",
"    </a>",
"    ]; head circumference also may be increased. The knee epiphyses often lack calcification, and this is more likely to occur in males than females (40 versus 28 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many infants are still born in regions of the world that lack newborn screening programs. Symptoms and signs that develop in these infants include lethargy, slow movement, hoarse cry, feeding problems, constipation, macroglossia, umbilical hernia, large fontanels, hypotonia, dry skin, hypothermia, and prolonged jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/62\">",
"     62",
"    </a>",
"    ]. A few newborn infants with thyroid dyshormonogenesis have a palpable goiter, but it usually appears later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Congenital malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital hypothyroidism appears to be associated with an increased risk of additional congenital malformations affecting the heart, kidneys, urinary tract, gastrointestinal and skeletal systems [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. As an example, in a population-based study of 1420 infants with congenital hypothyroidism, the prevalence of other congenital malformations (mostly cardiac) was fourfold higher (8.4 percent) than in the control infant population (1 to 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/63\">",
"     63",
"    </a>",
"    ]. In the New York State Congenital Malformation Registry (980 children), there was an increased risk of renal and urologic abnormalities (Odds Ratio 13.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/67\">",
"     67",
"    </a>",
"    ]. Infants with congenital hypothyroidism and cleft palate may have a TTF-2 (FOXE1) gene mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/20\">",
"     20",
"    </a>",
"    ]. Infants with persistent neurologic problems, including ataxia, are suspect for a NKX2.1 gene mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NEWBORN SCREENING PROGRAMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening of all newborns is now routine in all 50 states of the United States, and in Canada, Europe, Israel, Japan, Australia and New Zealand; screening programs are under development in Eastern Europe, South America, Asia, and Africa. In the United States, more than 4 million infants are screened annually, leading to the detection of 1600 infants with congenital hypothyroidism. Out of a worldwide birth population of approximately 130 million infants annually, it is estimated that 25 to 30 million infants (20 to 25 percent) are screened and 8,000 to 10,000 infants with hypothyroidism are detected annually.",
"   </p>",
"   <p>",
"    Blood for screening is collected onto filter paper cards after heel prick, usually two to five days after delivery. Some programs also routinely obtain a second specimen between two and six weeks after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/68\">",
"     68",
"    </a>",
"    ]. The cards are then sent to a centralized laboratory for testing.",
"   </p>",
"   <p>",
"    Three major screening strategies have evolved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial blood T4 assay, with follow-up TSH assay if the blood T4 value is below a certain concentration (usually less than the 10th percentile)",
"     </li>",
"     <li>",
"      Initial blood TSH assay",
"     </li>",
"     <li>",
"      Simultaneous T4 and TSH assay",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most states in the United States started with the initial",
"    <span class=\"nowrap\">",
"     T4/follow-up",
"    </span>",
"    TSH testing approach, but many states have switched to initial TSH testing. Either approach detects the majority of infants with congenital primary hypothyroidism, and each has its advantages. Infants with a delayed rise in blood TSH concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/69\">",
"     69",
"    </a>",
"    ] and those with central hypothyroidism can only be detected by the initial",
"    <span class=\"nowrap\">",
"     T4/follow-up",
"    </span>",
"    TSH assay method [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/70,71\">",
"     70,71",
"    </a>",
"    ], whereas infants with subclinical hypothyroidism (high blood TSH, normal blood T4) can only be detected by TSH testing.",
"   </p>",
"   <p>",
"    A retrospective study from a state that employs simultaneous measurement of T4 and TSH reported that only 19 percent of infants subsequently diagnosed with central hypothyroidism had a newborn screening result of T4 &lt;5",
"    <span class=\"nowrap\">",
"     micrograms/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/72\">",
"     72",
"    </a>",
"    ]. Thus, the majority of infants with central hypothyroidism will not be detected even by this screening approach, because their T4 result is above the screening cutoff. Thus, it is important to refer and evaluate infants who have clinical features suggestive of congenital hypopituitarism; clinicians should not be falsely reassured by a normal screening T4 result.",
"   </p>",
"   <p>",
"    Infants with blood TSH values above certain levels, usually 15",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    (serum TSH &gt;30",
"    <span class=\"nowrap\">",
"     mU/L),",
"    </span>",
"    are recalled for clinical evaluation and serum testing, which occurs between 1 and 3 weeks of age in well-run programs. The recall rate is approximately 0.05 percent, which means that two infants are recalled for everyone who proves to have congenital hypothyroidism. Programs that recall infants only on the basis of low blood T4 values have recall rates of approximately 0.3 percent.",
"   </p>",
"   <p>",
"    Screening with multiple tests (eg, T4 and TSH, or T4 and TSH and thyroxine-binding globulin [TBG]) has been suggested as a way to improve detection of both primary and central hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/73\">",
"     73",
"    </a>",
"    ]. However, the improved detection rate is associated with an increased number of false positive screens. False positive screens may lead to unnecessary parental anxiety as well as a potential rise in overall costs because of unnecessary recall of patients and need for further testing.",
"   </p>",
"   <p>",
"    It is possible that a \"false positive\" screen (reflecting transient elevations in TSH) is associated with an increased risk for mild thyroid disease. One study found that of 44 children with false positive screens due to hyperthyrotropinemia, 14 (32 percent) had subclinical hypothyroidism at age eight [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/74\">",
"     74",
"    </a>",
"    ]. The TSH elevation at eight years was mild (4.1 to 8.2",
"    <span class=\"nowrap\">",
"     mU/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with abnormal screening results are recalled for further testing. At recall, the infant should be examined and a blood sample is obtained by venipuncture to confirm the diagnosis of hypothyroidism (",
"    <a class=\"graphic graphic_algorithm graphicRef73836 \" href=\"UTD.htm?36/21/37200\">",
"     algorithm 1",
"    </a>",
"    ). If the diagnosis of hypothyroidism is confirmed, other studies (such as thyroid radionuclide uptake and imaging, ultrasonography, serum thyroglobulin, tests for thyroid autoantibodies, or urinary iodine excretion) may be performed to identify the cause. In the majority of cases, the decision to start thyroid hormone treatment is based on thyroid function test results. Thus, we consider additional diagnostic studies to identify a cause to be optional. There are some circumstances, discussed below, where these diagnostic tests do influence the treatment decision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Serum tests of thyroid function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings of low serum T4 or free T4 and high serum TSH values confirm the diagnosis of primary hypothyroidism. One must keep in mind that serum T4 concentrations are higher in the first few weeks of life in normal infants than in adults because of the surge in TSH secretion that occurs soon after birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40696?source=see_link\">",
"     \"Thyroid physiology and screening in preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Between one and four days of life, the normal range for serum total T4 concentrations is about 10 to 22",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (129 to 283",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      and the normal range for serum free T4 concentrations is about 2 to 5",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (25 to 64",
"      <span class=\"nowrap\">",
"       pmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Between one and four weeks of life, the normal range for serum total T4 concentrations is 7 to 16",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (90 to 206",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      and the normal range for serum free T4 concentrations is 0.8 to 2.0",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (10 to 26",
"      <span class=\"nowrap\">",
"       pmol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A normal serum total or free T4 concentration and a high serum TSH concentration define subclinical hypothyroidism. In cases where the serum TSH is marginally elevated (eg, 6 to 10",
"    <span class=\"nowrap\">",
"     mU/L),",
"    </span>",
"    one option is to monitor carefully, repeating a serum TSH and free T4 in a week. Some infants will normalize TSH without treatment using this approach. However, if the serum TSH does not normalize by four to six weeks of age, we recommend starting thyroid hormone treatment, because of the critical dependence of the developing central nervous system on adequate amounts of T4. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=see_link\">",
"     \"Subclinical hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In those programs that follow up with infants with low blood T4 screening results alone, low serum total and free T4 concentrations in the presence of low or normal serum TSH concentrations indicate the presence of central hypothyroidism. Rare infants who are ultimately proven to have primary hypothyroidism also may have low serum T4 and TSH values when recalled, because the expected rise in serum TSH is delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/75\">",
"     75",
"    </a>",
"    ]. Infants with either of these findings should be treated.",
"   </p>",
"   <p>",
"    Premature infants and infants with nonthyroidal illness also may have low serum total and free T4 and normal serum TSH concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/76\">",
"     76",
"    </a>",
"    ]. We do",
"    <strong>",
"     not",
"    </strong>",
"    recommend treatment for these infants unless there is other evidence of hypothalamic or pituitary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of a low serum total T4 concentration and normal serum free T4 and TSH concentrations indicates the presence of thyroxine-binding globulin (TBG) deficiency, an X-linked recessive disorder that occurs in approximately 1:4000 newborns, predominantly males [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/77\">",
"     77",
"    </a>",
"    ]. These infants are euthyroid and do not require treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Thyroid imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid ultrasonography or radionuclide uptake measurements and imaging (&ldquo;scan&rdquo;) provide information about the underlying etiology, eg, thyroid dysgenesis or one of the dyshormonogeneses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. We do",
"    <strong>",
"     not",
"    </strong>",
"    recommend either test routinely, because for most cases the results do not alter management. However, the tests may provide useful information in some infants. They are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants with minor abnormalities in thyroid function, in whom it is not clear whether thyroid hormone treatment is indicated (eg, TSH 5 to 10",
"      <span class=\"nowrap\">",
"       mU/L,",
"      </span>",
"      with free T4 in the normal reference range for age). In such an infant, the finding of ectopically located thyroid tissue would support a diagnosis of hypothyroidism.",
"     </li>",
"     <li>",
"      Infants with a small goiter in whom an enzymatic defect in T4 synthesis is suspected; most of these infants have normal or high uptake values in normally located if not enlarged thyroid glands. As these defects are hereditary (autosomal recessive), this finding allows counseling about risk in future children.",
"     </li>",
"     <li>",
"      Infants suspected of having transient hypothyroidism. The presence of reduced radionuclide uptake in normally located thyroid tissue supports a diagnosis of mild, possibly transient hypothyroidism. Cases of transient hypothyroidism due to transplacental passage of maternal TSH-receptor blocking antibodies (TRB-Ab) typically do not have radionuclide uptake or image on scanning, but on ultrasonography a normal thyroid gland may be visualized. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Transient congenital hypothyroidism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Thyroid ultrasonography and color flow Doppler",
"    </strong>",
"    &ndash; If the clinician chooses to do thyroid imaging, we recommend starting with ultrasound. If an ectopic thyroid gland is identified by ultrasound, radionuclide imaging will not be necessary, thus avoiding radiation exposure and expense. However, ultrasound is not as reliable as radionuclide imaging in identifying cases of thyroid dysgenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/80\">",
"     80",
"    </a>",
"    ]. In studies comparing the two procedures, some infants had ectopic thyroid tissue detected by radionuclide imaging, but the ultrasound images revealed either no thyroid tissue or thyroid hypoplasia; in some of the other infants, radionuclide imaging revealed thyroid agenesis or hypoplasia but the ultrasound images were normal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Color flow Doppler ultrasonography may be superior to gray scale ultrasonography. It detected ectopic thyroid tissue in 90 percent of infants with congenital hypothyroidism and ectopic tissue detected on radionucleotide imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/83\">",
"     83",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <strong>",
"     Thyroid radionucleotide uptake and scan",
"    </strong>",
"    &ndash; If the ultrasound study does not detect ectopic thyroid tissue, then a thyroid radionuclide uptake scan may help to identify cases of thyroid dysgenesis. Either 99m-pertechnetate or 123-I-iodine should be used, instead of 131-I-iodine, because the radiation doses are much lower. 99m-pertechnetate is more readily available and allows a good scan picture, but because it is not organified, there is no measure of uptake. 123-I must be specially ordered, due to its short half-life, but it will provide both a scan and a measure of uptake. A large gland in a normal location typically is seen with one of the enzymatic defects. A positive perchlorate discharge test is compatible with an organification defect [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Serum thyroglobulin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of serum thyroglobulin has been advocated as a means to distinguish among the causes of congenital hypothyroidism. One study reported low serum thyroglobulin concentrations in infants with thyroid agenesis (mean 12",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    range 2 to 54",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    intermediate concentrations in those with ectopic thyroid tissue (92",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    range 11 to 231",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    and high concentrations in those with goiters (226",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    range 3 to 425",
"    <span class=\"nowrap\">",
"     ng/mL);",
"    </span>",
"    the normal range was 20 to 80",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/39/2682/abstract/78\">",
"     78",
"    </a>",
"    ]. Given the degree of overlap among these groups, we do not think that measurement of serum thyroglobulin can substitute for radionuclide imaging, and do",
"    <strong>",
"     not",
"    </strong>",
"    recommend it except in puzzling cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Urinary iodine concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is a history of iodine exposure, or if the infant is born in an area of endemic goiter, measurement of urinary iodine can confirm an excess (or deficient) state. Usually, however, this information can be obtained by history. In infants thought to have iodine-induced hypothyroidism, any continuing iodine exposure should be discontinued and T4 therapy given for several months and then gradually withdrawn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/34/27170?source=see_link\">",
"       \"Patient information: Congenital hypothyroidism (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25506688\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital hypothyroidism occurs in approximately 1:2000 to 1:4000 newborns and is one of the most common preventable causes of intellectual disability (mental retardation). Newborn screening programs allow for early identification and treatment of affected infants to minimize complications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 85 percent of permanent cases of congenital hypothyroidism are sporadic, and most of these are caused by thyroid dysgenesis. The remaining 15 percent are hereditary, and may present during or after the neonatal period (",
"      <a class=\"graphic graphic_table graphicRef68356 \" href=\"UTD.htm?34/29/35292\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Thyroid dysgenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Disorders of thyroid hormone synthesis and secretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because some maternal thyroid hormone crosses the placenta, and because commonly there is some residual thyroid function in the neonate, the vast majority (more than 95 percent) of infants with congenital hypothyroidism are asymptomatic at birth. Rarely, newborns with congenital hypothyroidism present with lethargy, slow movement, hoarse cry, feeding problems, constipation, macroglossia, umbilical hernia, large fontanels, hypotonia, dry skin, hypothermia, and prolonged jaundice. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Newborn screening programs use one of the following strategies, each of which detects the majority of infants with congenital hypothyroidism:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Initial blood T4 assay, with follow-up TSH assay if the blood T4 value is below a certain concentration &ndash; This strategy detects infants with a delayed rise in blood TSH concentration and those with central hypothyroidism, but not those with subclinical primary hypothyroidism.",
"     </li>",
"     <li>",
"      Initial blood TSH assay &ndash; This strategy detects infants with subclinical hypothyroidism, but not those with central hypothyroidism.",
"     </li>",
"     <li>",
"      Simultaneous T4 and TSH assay &ndash; This strategy has the potential to detect all the thyroid disorders described with the above two screening approaches.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants with abnormal screening results are recalled for further testing. At recall, the infant should be examined and a blood sample obtained by venipuncture to confirm the diagnosis of hypothyroidism (",
"      <a class=\"graphic graphic_algorithm graphicRef73836 \" href=\"UTD.htm?36/21/37200\">",
"       algorithm 1",
"      </a>",
"      ). Age-specific norms must be used for interpretation, because T4 concentrations are higher in the first few weeks of life (and TSH in the first two years of life) than in older infants or adults. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Serum tests of thyroid function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The findings of low serum T4 or free T4 and high serum TSH values confirm the diagnosis of primary hypothyroidism. A normal serum total or free T4 concentration and a high serum TSH concentration define subclinical hypothyroidism. Low serum total and free T4 concentrations in the presence of low or normal serum TSH concentrations suggest central hypothyroidism (or primary hypothyroidism with delayed rise in TSH). Infants with any of these findings should be treated. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Serum tests of thyroid function'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15081?source=see_link\">",
"       \"Treatment and prognosis of congenital hypothyroidism\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      If the diagnosis of hypothyroidism is confirmed, other studies, such as thyroid radionuclide uptake and imaging, ultrasonography, serum thyroglobulin assay, tests for thyroid autoantibodies, or urinary iodine excretion, may be performed to identify the cause. These tests usually do not alter treatment; thus, they are considered optional, and we recommend that they be done only in special circumstances. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/1\">",
"      Klein AH, Meltzer S, Kenny FM. Improved prognosis in congenital hypothyroidism treated before age three months. J Pediatr 1972; 81:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/2\">",
"      Dussault JH, Coulombe P, Laberge C, et al. Preliminary report on a mass screening program for neonatal hypothyroidism. J Pediatr 1975; 86:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/3\">",
"      Gaudino R, Garel C, Czernichow P, L&eacute;ger J. Proportion of various types of thyroid disorders among newborns with congenital hypothyroidism and normally located gland: a regional cohort study. Clin Endocrinol (Oxf) 2005; 62:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/4\">",
"      Skordis N, Toumba M, Savva SC, et al. High prevalence of congenital hypothyroidism in the Greek Cypriot population: results of the neonatal screening program 1990-2000. J Pediatr Endocrinol Metab 2005; 18:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/5\">",
"      Harris KB, Pass KA. Increase in congenital hypothyroidism in New York State and in the United States. Mol Genet Metab 2007; 91:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/6\">",
"      Eug&egrave;ne D, Djemli A, Van Vliet G. Sexual dimorphism of thyroid function in newborns with congenital hypothyroidism. J Clin Endocrinol Metab 2005; 90:2696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/7\">",
"      Stoppa-Vaucher S, Van Vliet G, Delado&euml;y J. Variation by ethnicity in the prevalence of congenital hypothyroidism due to thyroid dysgenesis. Thyroid 2011; 21:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/8\">",
"      Nagasaki K, Asami T, Ogawa Y, et al. A study of the etiology of congenital hypothyroidism in the Niigata prefecture of Japan in patients born between 1989 and 2005 and evaluated at ages 5-19. Thyroid 2011; 21:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/9\">",
"      Fisher DA. Second International Conference on Neonatal Thyroid Screening: progress report. J Pediatr 1983; 102:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/10\">",
"      Devos H, Rodd C, Gagn&eacute; N, et al. A search for the possible molecular mechanisms of thyroid dysgenesis: sex ratios and associated malformations. J Clin Endocrinol Metab 1999; 84:2502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/11\">",
"      Macchia PE, Lapi P, Krude H, et al. PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat Genet 1998; 19:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/12\">",
"      Clifton-Bligh RJ, Wentworth JM, Heinz P, et al. Mutation of the gene encoding human TTF-2 associated with thyroid agenesis, cleft palate and choanal atresia. Nat Genet 1998; 19:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/13\">",
"      Vilain C, Rydlewski C, Duprez L, et al. Autosomal dominant transmission of congenital thyroid hypoplasia due to loss-of-function mutation of PAX8. J Clin Endocrinol Metab 2001; 86:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/14\">",
"      Castanet M, Lyonnet S, Bona&iuml;ti-Pelli&eacute; C, et al. Familial forms of thyroid dysgenesis among infants with congenital hypothyroidism. N Engl J Med 2000; 343:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/15\">",
"      Castanet M, Polak M, Bona&iuml;ti-Pelli&eacute; C, et al. Nineteen years of national screening for congenital hypothyroidism: familial cases with thyroid dysgenesis suggest the involvement of genetic factors. J Clin Endocrinol Metab 2001; 86:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/16\">",
"      L&eacute;ger J, Marinovic D, Garel C, et al. Thyroid developmental anomalies in first degree relatives of children with congenital hypothyroidism. J Clin Endocrinol Metab 2002; 87:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/17\">",
"      Perry R, Heinrichs C, Bourdoux P, et al. Discordance of monozygotic twins for thyroid dysgenesis: implications for screening and for molecular pathophysiology. J Clin Endocrinol Metab 2002; 87:4072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/18\">",
"      Doyle DA, Gonzalez I, Thomas B, Scavina M. Autosomal dominant transmission of congenital hypothyroidism, neonatal respiratory distress, and ataxia caused by a mutation of NKX2-1. J Pediatr 2004; 145:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/19\">",
"      Narumi S, Muroya K, Asakura Y, et al. Transcription factor mutations and congenital hypothyroidism: systematic genetic screening of a population-based cohort of Japanese patients. J Clin Endocrinol Metab 2010; 95:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/20\">",
"      Castanet M, Park SM, Smith A, et al. A novel loss-of-function mutation in TTF-2 is associated with congenital hypothyroidism, thyroid agenesis and cleft palate. Hum Mol Genet 2002; 11:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/21\">",
"      Baris I, Arisoy AE, Smith A, et al. A novel missense mutation in human TTF-2 (FKHL15) gene associated with congenital hypothyroidism but not athyreosis. J Clin Endocrinol Metab 2006; 91:4183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/22\">",
"      van Trotsenburg AS, Kempers MJ, Endert E, et al. Trisomy 21 causes persistent congenital hypothyroidism presumably of thyroidal origin. Thyroid 2006; 16:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/23\">",
"      Sunthornthepvarakui T, Gottschalk ME, Hayashi Y, Refetoff S. Brief report: resistance to thyrotropin caused by mutations in the thyrotropin-receptor gene. N Engl J Med 1995; 332:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/24\">",
"      Narumi S, Muroya K, Abe Y, et al. TSHR mutations as a cause of congenital hypothyroidism in Japan: a population-based genetic epidemiology study. J Clin Endocrinol Metab 2009; 94:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/25\">",
"      Cangul H, Morgan NV, Forman JR, et al. Novel TSHR mutations in consanguineous families with congenital nongoitrous hypothyroidism. Clin Endocrinol (Oxf) 2010; 73:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/26\">",
"      Persani L, Gelmini G, Marelli F, et al. Syndromes of resistance to TSH. Ann Endocrinol (Paris) 2011; 72:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/27\">",
"      Lado-Abeal J, Castro-Piedras I, Palos-Paz F, et al. A family with congenital hypothyroidism caused by a combination of loss-of-function mutations in the thyrotropin receptor and adenylate cyclase-stimulating G alpha-protein subunit genes. Thyroid 2011; 21:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/28\">",
"      Bakker B, Bikker H, Vulsma T, et al. Two decades of screening for congenital hypothyroidism in The Netherlands: TPO gene mutations in total iodide organification defects (an update). J Clin Endocrinol Metab 2000; 85:3708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/29\">",
"      Pohlenz J, Rosenthal IM, Weiss RE, et al. Congenital hypothyroidism due to mutations in the sodium/iodide symporter. Identification of a nonsense mutation producing a downstream cryptic 3' splice site. J Clin Invest 1998; 101:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/30\">",
"      Vigone MC, Fugazzola L, Zamproni I, et al. Persistent mild hypothyroidism associated with novel sequence variants of the DUOX2 gene in two siblings. Hum Mutat 2005; 26:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/31\">",
"      Moreno JC, Bikker H, Kempers MJ, et al. Inactivating mutations in the gene for thyroid oxidase 2 (THOX2) and congenital hypothyroidism. N Engl J Med 2002; 347:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/32\">",
"      Zamproni I, Grasberger H, Cortinovis F, et al. Biallelic inactivation of the dual oxidase maturation factor 2 (DUOXA2) gene as a novel cause of congenital hypothyroidism. J Clin Endocrinol Metab 2008; 93:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/33\">",
"      Pardo V, Rubio IG, Knobel M, et al. Phenotypic variation among four family members with congenital hypothyroidism caused by two distinct thyroglobulin gene mutations. Thyroid 2008; 18:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/34\">",
"      Moreno JC, Klootwijk W, van Toor H, et al. Mutations in the iodotyrosine deiodinase gene and hypothyroidism. N Engl J Med 2008; 358:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/35\">",
"      Friesema EC, Grueters A, Biebermann H, et al. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet 2004; 364:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/36\">",
"      Hanna CE, Krainz PL, Skeels MR, et al. Detection of congenital hypopituitary hypothyroidism: ten-year experience in the Northwest Regional Screening Program. J Pediatr 1986; 109:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/37\">",
"      Collu R, Tang J, Castagn&eacute; J, et al. A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene. J Clin Endocrinol Metab 1997; 82:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/38\">",
"      Medeiros-Neto G, Herodotou DT, Rajan S, et al. A circulating, biologically inactive thyrotropin caused by a mutation in the beta subunit gene. J Clin Invest 1996; 97:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/39\">",
"      Doeker BM, Pf&auml;ffle RW, Pohlenz J, Andler W. Congenital central hypothyroidism due to a homozygous mutation in the thyrotropin beta-subunit gene follows an autosomal recessive inheritance. J Clin Endocrinol Metab 1998; 83:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/40\">",
"      van Tijn DA, de Vijlder JJ, Vulsma T. Role of the thyrotropin-releasing hormone stimulation test in diagnosis of congenital central hypothyroidism in infants. J Clin Endocrinol Metab 2008; 93:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/41\">",
"      Kempers MJ, van Tijn DA, van Trotsenburg AS, et al. Central congenital hypothyroidism due to gestational hyperthyroidism: detection where prevention failed. J Clin Endocrinol Metab 2003; 88:5851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/42\">",
"      Higuchi R, Miyawaki M, Kumagai T, et al. Central hypothyroidism in infants who were born to mothers with thyrotoxicosis before 32 weeks' gestation: 3 cases. Pediatrics 2005; 115:e623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/43\">",
"      Kempers MJ, van Trotsenburg AS, van Rijn RR, et al. Loss of integrity of thyroid morphology and function in children born to mothers with inadequately treated Graves' disease. J Clin Endocrinol Metab 2007; 92:2984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/44\">",
"      Delange F, Dalhem A, Bourdoux P, et al. Increased risk of primary hypothyroidism in preterm infants. J Pediatr 1984; 105:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/45\">",
"      Zakarija M, McKenzie JM, Eidson MS. Transient neonatal hypothyroidism: characterization of maternal antibodies to the thyrotropin receptor. J Clin Endocrinol Metab 1990; 70:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/46\">",
"      Brown RS, Bellisario RL, Mitchell E, et al. Detection of thyrotropin binding inhibitory activity in neonatal blood spots. J Clin Endocrinol Metab 1993; 77:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/47\">",
"      Iseki M, Shimizu M, Oikawa T, et al. Sequential serum measurements of thyrotropin binding inhibitor immunoglobulin G in transient familial neonatal hypothyroidism. J Clin Endocrinol Metab 1983; 57:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/48\">",
"      Pacaud D, Huot C, Gattereau A, et al. Outcome in three siblings with antibody-mediated transient congenital hypothyroidism. J Pediatr 1995; 127:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/49\">",
"      Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest 2001; 24:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/50\">",
"      Cosman BC, Schullinger JN, Bell JJ, Regan JA. Hypothyroidism caused by topical povidone-iodine in a newborn with omphalocele. J Pediatr Surg 1988; 23:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/51\">",
"      Rodesch F, Camus M, Ermans AM, et al. Adverse effect of amniofetography on fetal thyroid function. Am J Obstet Gynecol 1976; 126:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/52\">",
"      Atwell TD, Lteif AN, Brown DL, et al. Neonatal thyroid function after administration of IV iodinated contrast agent to 21 pregnant patients. AJR Am J Roentgenol 2008; 191:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/53\">",
"      Bourjeily G, Chalhoub M, Phornphutkul C, et al. Neonatal thyroid function: effect of a single exposure to iodinated contrast medium in utero. Radiology 2010; 256:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/54\">",
"      Mouat F, Evans HM, Cutfield WS, et al. Massive hepatic hemangioendothelioma and consumptive hypothyroidism. J Pediatr Endocrinol Metab 2008; 21:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/55\">",
"      Maruo Y, Takahashi H, Soeda I, et al. Transient congenital hypothyroidism caused by biallelic mutations of the dual oxidase 2 gene in Japanese patients detected by a neonatal screening program. J Clin Endocrinol Metab 2008; 93:4261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/56\">",
"      Hulur I, Hermanns P, Nestoris C, et al. A single copy of the recently identified dual oxidase maturation factor (DUOXA) 1 gene produces only mild transient hypothyroidism in a patient with a novel biallelic DUOXA2 mutation and monoallelic DUOXA1 deletion. J Clin Endocrinol Metab 2011; 96:E841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/57\">",
"      Alm J, Hagenfeldt L, Larsson A, Lundberg K. Incidence of congenital hypothyroidism: retrospective study of neonatal laboratory screening versus clinical symptoms as indicators leading to diagnosis. Br Med J (Clin Res Ed) 1984; 289:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/58\">",
"      Vulsma T, Gons MH, de Vijlder JJ. Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. N Engl J Med 1989; 321:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/59\">",
"      Shoham I, Aricha-Tamir B, Weintraub AY, et al. Fetal heart rate tracing patterns associated with congenital hypothyroidism. Am J Obstet Gynecol 2009; 201:48.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/60\">",
"      Law WY, Bradley DM, Lazarus JH, et al. Congenital hypothyroidism in Wales (1982-1993): demographic features, clinical presentation and effects on early neurodevelopment. Clin Endocrinol (Oxf) 1998; 48:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/61\">",
"      Van Vliet G, Larroque B, Bubuteishvili L, et al. Sex-specific impact of congenital hypothyroidism due to thyroid dysgenesis on skeletal maturation in term newborns. J Clin Endocrinol Metab 2003; 88:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/62\">",
"      LaFranchi SH, Murphey WH, Foley TP Jr, et al. Neonatal hypothyroidism detected by the Northwest Regional Screening Program. Pediatrics 1979; 63:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/63\">",
"      Olivieri A, Stazi MA, Mastroiacovo P, et al. A population-based study on the frequency of additional congenital malformations in infants with congenital hypothyroidism: data from the Italian Registry for Congenital Hypothyroidism (1991-1998). J Clin Endocrinol Metab 2002; 87:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/64\">",
"      Siebner R, Merlob P, Kaiserman I, Sack J. Congenital anomalies concomitant with persistent primary congenital hypothyroidism. Am J Med Genet 1992; 44:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/65\">",
"      Roberts HE, Moore CA, Fernhoff PM, et al. Population study of congenital hypothyroidism and associated birth defects, Atlanta, 1979-1992. Am J Med Genet 1997; 71:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/66\">",
"      Al-Jurayyan NA, Al-Herbish AS, El-Desouki MI, et al. Congenital anomalies in infants with congenital hypothyroidism: is it a coincidental or an associated finding? Hum Hered 1997; 47:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/67\">",
"      Kumar J, Gordillo R, Kaskel FJ, et al. Increased prevalence of renal and urinary tract anomalies in children with congenital hypothyroidism. J Pediatr 2009; 154:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/68\">",
"      American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association, et al. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics 2006; 117:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/69\">",
"      LaFranchi SH, Hanna CE, Krainz PL, et al. Screening for congenital hypothyroidism with specimen collection at two time periods: results of the Northwest Regional Screening Program. Pediatrics 1985; 76:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/70\">",
"      Asami T, Otabe N, Wakabayashi M, et al. Congenital hypothyroidism with delayed rise in serum TSH missed on newborn screening. Acta Paediatr Jpn 1995; 37:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/71\">",
"      van Tijn DA, de Vijlder JJ, Verbeeten B Jr, et al. Neonatal detection of congenital hypothyroidism of central origin. J Clin Endocrinol Metab 2005; 90:3350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/72\">",
"      Nebesio TD, McKenna MP, Nabhan ZM, Eugster EA. Newborn screening results in children with central hypothyroidism. J Pediatr 2010; 156:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/73\">",
"      Lanting CI, van Tijn DA, Loeber JG, et al. Clinical effectiveness and cost-effectiveness of the use of the thyroxine/thyroxine-binding globulin ratio to detect congenital hypothyroidism of thyroidal and central origin in a neonatal screening program. Pediatrics 2005; 116:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/74\">",
"      Leonardi D, Polizzotti N, Carta A, et al. Longitudinal study of thyroid function in children with mild hyperthyrotropinemia at neonatal screening for congenital hypothyroidism. J Clin Endocrinol Metab 2008; 93:2679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/75\">",
"      Larson C, Hermos R, Delaney A, et al. Risk factors associated with delayed thyrotropin elevations in congenital hypothyroidism. J Pediatr 2003; 143:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/76\">",
"      Fisher DA. Euthyroid low thyroxine (T4) and triiodothyronine (T3) states in prematures and sick neonates. Pediatr Clin North Am 1990; 37:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/77\">",
"      Mandel S, Hanna C, Boston B, et al. Thyroxine-binding globulin deficiency detected by newborn screening. J Pediatr 1993; 122:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/78\">",
"      Muir A, Daneman D, Daneman A, Ehrlich R. Thyroid scanning, ultrasound, and serum thyroglobulin in determining the origin of congenital hypothyroidism. Am J Dis Child 1988; 142:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/79\">",
"      Schoen EJ, Clapp W, To TT, Fireman BH. The key role of newborn thyroid scintigraphy with isotopic iodide (123I) in defining and managing congenital hypothyroidism. Pediatrics 2004; 114:e683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/80\">",
"      Supakul N, Delaney LR, Siddiqui AR, et al. Ultrasound for primary imaging of congenital hypothyroidism. AJR Am J Roentgenol 2012; 199:W360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/81\">",
"      Takashima S, Nomura N, Tanaka H, et al. Congenital hypothyroidism: assessment with ultrasound. AJNR Am J Neuroradiol 1995; 16:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/82\">",
"      Chang YW, Lee DH, Hong YH, et al. Congenital hypothyroidism: analysis of discordant US and scintigraphic findings. Radiology 2011; 258:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/83\">",
"      Ohnishi H, Sato H, Noda H, et al. Color Doppler ultrasonography: diagnosis of ectopic thyroid gland in patients with congenital hypothyroidism caused by thyroid dysgenesis. J Clin Endocrinol Metab 2003; 88:5145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/39/2682/abstract/84\">",
"      Dias VM, Campos AP, Chagas AJ, Silva RM. Congenital hypothyroidism: etiology. J Pediatr Endocrinol Metab 2010; 23:815.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5836 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-C38B34FA94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_39_2682=[""].join("\n");
var outline_f2_39_2682=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25506688\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Thyroid dysgenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Resistance to TSH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Disorders of thyroid hormone synthesis and secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Defects in thyroid hormone transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22687023\">",
"      Defects in thyroid hormone metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22687042\">",
"      Resistance to thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Transient congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Congenital malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NEWBORN SCREENING PROGRAMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Serum tests of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Thyroid imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Serum thyroglobulin concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Urinary iodine concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25506688\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5836\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5836|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?36/21/37200\" title=\"algorithm 1\">",
"      Congenital hypothyroid screen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5836|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/29/27088\" title=\"figure 1\">",
"      Thyroid hormone synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5836|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/29/35292\" title=\"table 1\">",
"      Causes of congenital hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24280?source=related_link\">",
"      Congenital and acquired goiter in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20568?source=related_link\">",
"      Iodine-induced thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/34/27170?source=related_link\">",
"      Patient information: Congenital hypothyroidism (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=related_link\">",
"      Reduced sensitivity to thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=related_link\">",
"      Resistance to thyrotropin and thyrotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3850?source=related_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=related_link\">",
"      Thyroid function in nonthyroidal illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=related_link\">",
"      Thyroid hormone synthesis and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40696?source=related_link\">",
"      Thyroid physiology and screening in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15081?source=related_link\">",
"      Treatment and prognosis of congenital hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_39_2683="Menstrual history in pregnancy";
var content_f2_39_2683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Initial prenatal menstrual history",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Last menstrual period (definite or uncertain?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Last normal menstrual period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous menstrual period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cycle length",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent use of hormonal contraception?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Menarche",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         History of IUD use?_____&nbsp;&nbsp;",
"        </strong>",
"        <strong>",
"         Date removed:_____",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_39_2683=[""].join("\n");
var outline_f2_39_2683=null;
var title_f2_39_2684="Features OD 1p19q deletion";
var content_f2_39_2684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Typical features of oligodendroglial tumors with and without codeletion of chromosomes 1p/19q",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Codeletion of 1p/19q present",
"       </td>",
"       <td class=\"subtitle1\">",
"        Codeletion of 1p/19q absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other genetic alterations",
"       </td>",
"       <td>",
"        p16 deletions often present in anaplastic tumors",
"       </td>",
"       <td>",
"        p53 mutations, EGFR amplification, loss of 10 and 10q",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histology features",
"       </td>",
"       <td>",
"        Classical oligodendroglial morphology",
"       </td>",
"       <td>",
"        Astrocytic elements present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Localization",
"       </td>",
"       <td>",
"        Frontal, parietal, occipital",
"       </td>",
"       <td>",
"        Temporal, deep basal ganglia, diencephalon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MRI features",
"       </td>",
"       <td>",
"        <p>",
"         Indistinct borders and mixed signal intensity on T1- and T2-weighted images",
"        </p>",
"        <p>",
"         Diffuse, patchy enhancement",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Homogeneous T1 and T2 signal intensity, distinct borders",
"        </p>",
"        <p>",
"         Ring enhancement, necrosis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemotherapy responsiveness",
"       </td>",
"       <td>",
"        80 to 100 percent of tumors responding, with relatively long duration of response",
"       </td>",
"       <td>",
"        Objective response less frequent and of shorter duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Natural history",
"       </td>",
"       <td>",
"        Often present with indolent tumors and seizures only",
"       </td>",
"       <td>",
"        More rapid clinical progression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Median survival (anaplastic tumors)",
"       </td>",
"       <td>",
"        Greater than 10 years when surgery followed by combined radiation therapy plus chemotherapy",
"       </td>",
"       <td>",
"        Two to three years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_39_2684=[""].join("\n");
var outline_f2_39_2684=null;
var title_f2_39_2685="Dyspareunia differential dx3";
var content_f2_39_2685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnoses for physical causes of dyspareunia (cont.)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Location affected",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Important history",
"       </td>",
"       <td class=\"subtitle1\">",
"        Source of dyspareunia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments and Caveats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vestibule only",
"       </td>",
"       <td>",
"        Vestibulodynia",
"       </td>",
"       <td>",
"        Pain mainly with penetration, tampon or speculum",
"       </td>",
"       <td>",
"        Tenderness on touch or pressure, erythema",
"       </td>",
"       <td>",
"        No cause for the pain is found",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Perineum and anus",
"       </td>",
"       <td>",
"        Episiotomy",
"       </td>",
"       <td>",
"        Vaginal delivery with episiotomy",
"       </td>",
"       <td>",
"        Non-healing, tenderness",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatitis (eczema)",
"       </td>",
"       <td>",
"        Itching, irritation",
"       </td>",
"       <td>",
"        Erythema, edema, fissuring",
"       </td>",
"       <td>",
"        Look for Candida",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory bowel: Crohn's",
"       </td>",
"       <td>",
"        Diarrhea, bleeding, pain",
"       </td>",
"       <td>",
"        Edema, tags, fissures, sinuses",
"       </td>",
"       <td>",
"        May precede bowel symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rectum",
"       </td>",
"       <td>",
"        Rectocele",
"       </td>",
"       <td>",
"        Sensation of vaginal obstruction",
"       </td>",
"       <td>",
"        Protrusion of stool filled rectum",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Vagina&nbsp;",
"       </td>",
"       <td>",
"        Pelvic floor hypertonus",
"       </td>",
"       <td>",
"        Aching pain, vaginismus",
"       </td>",
"       <td>",
"        Levator spasm on palpation",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital anomaly: vaginal agenesis, imperforate hymen",
"       </td>",
"       <td>",
"        Inability to be penetrated",
"       </td>",
"       <td>",
"        Absent vagina, abn hymen",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Pelvis",
"       </td>",
"       <td>",
"        Retroverted or prolapsed uterus",
"       </td>",
"       <td>",
"        Pain with thrusting",
"       </td>",
"       <td>",
"        Uterine retroversion or descent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leiomyomata",
"       </td>",
"       <td>",
"        Pain with thrusting",
"       </td>",
"       <td>",
"        Tender uterine masses",
"       </td>",
"       <td>",
"        Uncommon cause of pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endometriosis, adenomyosis",
"       </td>",
"       <td>",
"        Cramping, deep dyspareunia; history of menorrhagia, dysmenorrhea",
"       </td>",
"       <td>",
"        Tender uterus, fixed uterus, nodules cul de sac rectovaginal septum, adnexal tenderness or masses",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adnexal pathology",
"       </td>",
"       <td>",
"        Deep dyspareunia, cyclical",
"       </td>",
"       <td>",
"        Tenderness in adnexa",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic inflammatory disease",
"       </td>",
"       <td>",
"        Chronic pelvic pain, deep dyspareunia",
"       </td>",
"       <td>",
"        Uterine, cervical, adnexal tenderness",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritable bowel syndrome",
"       </td>",
"       <td>",
"        Deep dyspareunia",
"       </td>",
"       <td>",
"        None; or pelvic tenderness",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Elizabeth Gunther Stewart, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_39_2685=[""].join("\n");
var outline_f2_39_2685=null;
var title_f2_39_2686="Quantitative real time PCR";
var content_f2_39_2686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Quantitative real-time polymerase chain reaction (PCR)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 462px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The mechanism of quantitative real-time PCR, which is based upon a probe that contains a fluorogenic reporter dye at its 5' end and a quencher at the 3' end (shown as a black line with a white box and a Q at its 5' and 3' end, respectively). With this technique, the tagged probe, which is designed to hybridize to one strand of the target DNA sequence (blue line), is added to a normal PCR. The quencher blocks fluorescence emission as long as it is in close proximity to the reporter. As the primer extends downstream during amplification (extended green arrow), the exonuclease activity of the DNA polymerase cleaves away the hybridized probe and removes the connection between the&nbsp;fluorescent dye (black box) and the quencher (Q). An increase in fluorescence signal ensues as more amplicons are generated.",
"    <div class=\"footnotes\">",
"     Q: quencher.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_39_2686=[""].join("\n");
var outline_f2_39_2686=null;
var title_f2_39_2687="Arteriovenous anastomosis postablation 3";
var content_f2_39_2687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arteriovenous anastomosis postablation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ablated (blanched) area between the recipient vein at 12 o'clock and the donor artery at 5 o'clock.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth J Moise, Jr, MD and Anthony Johnson, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_39_2687=[""].join("\n");
var outline_f2_39_2687=null;
